Document:

EX-10.10

 EXHIBIT 10.10 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

EXCLUSIVE LICENSE AGREEMENT 
 This Exclusive License Agreement (the “Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers
under the laws of the State of California, and FATE THERAPEUTICS, INC. (“Fate”), a corporation having a principal place of business at 3535 General Atomics Court, Suite 200, San Diego, CA 92121, is effective on the 2nd day of May, 2013 (“Effective Date”). 

 

	 	1	BACKGROUND 

 Stanford has
an assignment of an invention “Wnt Compositions and Methods of Use Thereof” that was invented in the laboratory of Dr. Christopher Garcia, a Howard Hughes Medical Institute (“HHMI”) medical investigator, and is described in
Stanford Docket [***]. The invention was made in the course of research supported by HHMI. Stanford wants to have the invention perfected and marketed as soon as possible so that resulting products may be available for public use and benefit.

  

	 	2	DEFINITIONS 

  

	 	2.1	“Affiliates” means any person, corporation, or other business entity which controls, is controlled by, or is under common control with Fate; and for this
purpose, ‘control’ of a corporation means the direct or indirect ownership of at least fifty percent (50%) of its voting stock, and “control” of any other business entity means the direct or indirect ownership of a fifty
percent (50%) or greater interest in the income of such entity. 

  

	 	2.2	“Confidential Information” means any and all reports and records provided by Fate to Stanford in accordance with this Agreement, including reports under
Sections 6.3, 8.1, and 8.3, and records under Section 8.4. Information shall not be considered confidential to the extent that either party can establish by competent proof that it: 

(a) Is publicly disclosed through no fault of the receiving party, either before or after it becomes known to the receiving party; or

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.

 (b) Was known to the receiving party without obligation of confidentiality prior to the date
of this Agreement, which knowledge was acquired independently and not from the disclosing party (including such party’s employees, consultants or agents); or 
 (c) Is subsequently disclosed to the receiving party without obligation of confidentiality in good faith by a third party who is not under any obligation to maintain the confidentiality of such
information, and without breach of this Agreement by a receiving party; or 
 (d) Has been published by a third party not in
breach of any obligation of confidentiality; or 
 (e) Was independently developed by the receiving party without the use of or
reliance on the Confidential Information of the disclosing party. 
  

	 	2.3	“Customer” means any individual or entity that receives Licensed Products for their own end use and not for further sale, transfer, lease, exchange or other
disposition. For clarity, an Affiliate or sublicensee shall be deemed a Customer only to the extent it is an end user of the Licensed Products that are not intended for further sale, transfer, lease, exchange or other disposition.

  

	 	2.4	“Exclusive” means that, subject to Articles 3 and 5, as applicable, Stanford has not and will not grant further licenses under the Licensed Patents in the
Licensed Field of Use in the Licensed Territory. 

  

	 	2.5	“HHMI Indemnitees” means HHMI and its trustees, officers, employees, and agents. 

 

	 	2.6	“Licensed Field of Use” means the treatment, prevention, palliation of diseases, conditions, syndromes and maladies of humans and animals.

  

	 	2.7	“Licensed Patents” means (i) Stanford’s [***], and any patent applications corresponding thereto; (ii) patents issued from [***], and from
divisionals and continuations of these applications and any reissues of such patents; (iii) claims of continuation-in-part applications and patents directed to subject matter specifically described in [***]; and (iv) claims of all foreign
patent applications, patents, and other intellectual property which are directed to subject matter specifically described in [***]. 

  

	 	2.8	“Licensed Product” means any device, composition, product or part of a product in the Licensed Field of Use, the manufacture, use, sale, offer for sale or
import of which, but for the licenses granted herein, would infringe a Valid Claim of a Licensed Patent. 

  
  

	* 	 Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  
  

Page: 2 of 34 

	 	2.9	“Licensed Territory” means worldwide. 

  

	 	2.10	“Net Sales” means all gross revenue actually received by Fate, its Affiliates or sublicensees from the sale of Licensed Products to Customers. Net Sales
excludes the following items (but only as they pertain to the making, using, importing or selling of Licensed Products, are included in gross revenue, and are separately itemized): 

 

	 	(A)	import, export, excise, tariff, use and sales taxes, and custom duties; 

  

	 	(B)	costs of insurance, packing, and transportation from the place of manufacture to the customer’s premises or point of installation; 

 

	 	(C)	costs of installation at the place of use; 

  

	 	(D)	credit for returns, rejections, allowances, recall expenses, or trades; 

  

	 	(E)	cash, trade or quantity discounts actually granted to Customers and retroactive price reductions applicable to sales of Licensed Products; and 

 

	 	(F)	fees paid to distributors. 

 For
the avoidance of doubt, transfers of a Licensed Product between any of Fate, an Affiliate or a sublicensee for sale by the transferee shall not be considered Net Sales hereunder. 

If a Licensed Product is sold or used in combination with one or more products, compositions, processes or services which are not Licensed
Products (hereinafter collectively, “Combination Product”), then Net Sales from such Combination Product means the gross revenue actually received for the sale to Customers, less the deductions set forth above, multiplied by a proration
factor. This proration factor shall be determined as follows: 
  

	 	(1)	If on a country-by-country basis all components of the Combination Product were sold separately, the proration factor shall be determined by the formula [A/(A+B)],
where A is the average gross selling price of the Licensed Product components sold separately by Fate, its Affiliates or sublicensee, and B is the average gross selling price of such other components of the Combination Product when sold separately;

  

	 	(2)	If on a country-by-country basis the other component(s) other than the Licensed Product in the Combination Product were not all sold separately, the proration factor
shall be determined by the formula A/C, where A is the average gross selling price of the Licensed Product sold separately by Fate, its Affiliates or sublicensee, and C is the average gross selling price of the Combination Product; or

  

	 	(3)	If on a country-by-country basis neither the Licensed Product nor all of the other component(s) in the Combination Product were sold separately, then the proration
factor shall be determined in a consistent and equitable manner that reflects the contribution of the Licensed Product to the payments received from Net Sales of such Licensed Product as the parties shall in good faith negotiate and agree.

  
  

Page: 3 of 34 

	 	2.11	“Stanford Indemnitees” means Stanford and Stanford Hospitals and Clinics, and their respective trustees, officers, employees, students, and agents.

  

	 	2.12	“Sublicensing Revenue” means all upfront fees and other payments received by Fate from all sublicensees in consideration of a grant of rights to the Licensed
Patents by Fate to such sublicensees. The following consideration or payments received by Fate shall be excluded from the calculation of sublicensing consideration due to Stanford with respect to an applicable sublicense: (i) royalties paid by
sublicensees (which will be at the Earned Royalty rate specified in Section 7.6); (ii) equity or debt at fair market value; (iii) payments to reimburse patent prosecution, defense, enforcement costs and maintenance and/or other
related expenses; (iv) reimbursements for costs for research, development or commercialization activities (including payments for full time employees); and (v) milestone payments to the extent that Fate pays Stanford the milestone amounts
specified in Section 7.5. To the extent that rights other than the Licensed Patents are sublicensed, the consideration received will be equitably apportioned between those Patent Rights and those other rights. In the event that Stanford
disputes the apportionment of consideration, the parties agree to meet and discuss to resolve the issue. 

  

	 	2.13	“Valid Claim” means (a) a claim in an issued and unexpired patent included in the Licensed Patents that: (i) has not been held unenforceable,
unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, and is not subject to appeal, (ii) has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise,
(iii) has not been lost through an interference, reexamination or reissue proceeding; or (b) a pending claim of a patent application included in the Licensed Patents that has not been pending for more than seven years or cancelled,
withdrawn, abandoned or finally disallowed, without the possibility of appeal or refiling of such application. 

  

	 	3	GRANT 

  

	 	3.1	Grant. Subject to the terms and conditions of this Agreement, Stanford hereby grants Fate and Fate’s Affiliates a license under the Licensed Patents in the
Licensed Field of Use to make, have made, use, have used, sell, have sold, offer to sell, have offered to sell, lease, have leased, import and have imported Licensed Products in the Licensed Territory. 

 

	 	3.2	Exclusivity. The license is Exclusive, including the right to sublicense under Article 4, in the Licensed Field of Use during the Term of this Agreement.

  

	 	3.3	 Retained Rights. Stanford retains the right, on behalf of itself and all other non-profit academic research institutions, to practice the
Licensed Patents for any non-profit purpose, including sponsored research and collaborations. Fate agrees that, notwithstanding any other provision of this Agreement, it has no right to enforce the Licensed Patent against any such institution.
Stanford and any such other 

  
  

Page: 4 of 34 

	 	
institution have the right to publish any information included in the Licensed Patents. Fate acknowledges that Stanford has granted to HHMI a perpetual, paid-up, irrevocable, worldwide,
royalty-free, nonexclusive, nontransferable license to use the Licensed Patents for HHMI’s research purposes, but with no right to assign or sublicense (“HHMI License”). The licenses granted are explicitly made subject to the HHMI
License. 

  

	 	3.4	Specific Exclusion. Stanford does not: 

  

	 	(A)	grant to Fate any other licenses, implied or otherwise, to any patents or other rights of Stanford other than those rights granted under the Licensed Patents,
regardless of whether the patents or other rights are dominant or subordinate to any Licensed Patents, or are required to exploit any Licensed Patents; 

  

	 	(B)	commit to Fate to bring suit against third parties for infringement, except as described in Article 14; and 

 

	 	(C)	agree to furnish to Fate any technology or technological information or to provide Fate with any assistance. 

 

	 	3.5	[***]. 

  

	 	4	SUBLICENSING 

  

	 	4.1	Permitted Sublicensing. Fate may grant sublicenses under the rights granted in Section 3.1 in the Licensed Field of Use only if Fate is actively pursuing
development or commercialization of Licensed Products. Sublicenses with any exclusivity must include diligence requirements sufficient to enable Fate and sublicensee to comply with this Agreement.  

 

	 	4.2	Required Sublicensing. If Fate is unable or unwilling to serve or develop a potential market or market territory for which there is a company willing to be a
sublicensee, Fate will, at Stanford’s written request, negotiate in good faith a sublicense with any such sublicensee. Stanford would like licensees to address unmet needs, such as those of neglected patient populations or geographic areas,
giving particular attention to improved therapeutics, diagnostics and agricultural technologies for the developing world. 

  

	 	4.3	Any sublicense: 

  

	 	(A)	is subject to this Agreement; 

  

	 	(B)	will reflect that any sublicensee will not further sublicense without prior written consent from Stanford, which consent shall not be unreasonably withheld;

  

	 	(C)	will prohibit sublicensee from paying royalties to an escrow or other similar account; 

  
  

	* 	 Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  
  

Page: 5 of 34 

	 	(D)	will expressly include the provisions of Articles 8, 9, 10, 13 and Section 20.5 for the benefit of Stanford and/or HHMI as the case may be; and

  

	 	(E)	will include the provisions of Section 4.4 and require the transfer of all the sublicensee’s obligations to Fate, including the payment of royalties specified
in the sublicense, to Stanford or its designee, if this Agreement is terminated. 

  

	 	4.4	Litigation by Sublicensee. Any sublicense must include the following clauses: 

 

	 	(A)	In the event sublicensee brings any court action seeking to invalidate any Licensed Patent: 

 

	 	(1)	sublicensee will [***] during the pendency of such action. Moreover, should the outcome of such action determine that any claim of a Licensed Patent challenged by the
sublicensee is both valid and infringed by a Licensed Product, sublicensee will [***]; 

  

	 	(2)	sublicensee will have no right to recoup any royalties paid before or during the period challenge; 

 

	 	(3)	any dispute regarding the validity of any Licensed Patent shall be litigated in the courts located in Santa Clara County, and the parties agree not to challenge
personal jurisdiction in that forum; 

  

	 	(4)	sublicensee shall not pay royalties into any escrow or other similar account. 

 

	 	(B)	Sublicensee will provide written notice to Stanford at least [***] prior to bringing an action seeking to invalidate a Licensed Patent. Sublicensee will include with
such written notice an identification of all prior art it believes invalidates any claim of the Licensed Patent. 

  

	 	4.5	Copy of Sublicenses. Fate will submit to Stanford a copy of each sublicense. Fate may redact those portions of such sublicense(s) that are not necessary for
Stanford to determine whether Fate is in compliance with its obligations under this Agreement. Each sublicense and any information provided by Fate to Stanford under this Article 4 shall be deemed to be Confidential Information of Fate.

  

	 	4.6	Sharing of Sublicensing Revenue. Fate will pay to Stanford: 

  

	 	(A)	[***] percent ([***]%) of Sublicensing Revenue received by Fate from sublicensees for sublicenses to the Licensed Patents granted [***]. 

 

	 	(B)	[***] percent ([***]%) of Sublicensing Revenue received by Fate from sublicensees for sublicenses to the Licensed Patents granted [***]. 

  
  

	* 	 Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  
  

Page: 6 of 34 

	 	(C)	[***] percent ([***]%) of Sublicensing Revenue received by Fate from sublicensees for sublicenses to the Licensed Patents granted [***]. 

Notwithstanding the foregoing, in the event that rights other than the Licensed Patents are sublicensed, the consideration received will
be equitably apportioned between the Patent Rights and those other rights, and it is understood and agreed by the parties that the maximum aggregate amount payable by Fate to Stanford with respect to such sublicense, whether such revenue is owed as
Sublicensing Revenue under this Agreement or any other license agreements entered into between Fate and Stanford, shall not be greater than [***] percent ([***]%) of all upfront fees and other payments received by Fate in consideration of the grant
of such sublicense. 
  

	 	4.7	Royalty-Free Sublicenses. If Fate pays all royalties due Stanford under this Agreement from a sublicensee’s Net Sales, Fate may grant that sublicensee a
royalty-free or non-cash: 

  

	 	(A)	sublicense or 

  

	 	(B)	cross-license. 

  

	 	4.8	Permitted Subcontracting. The license granted by Stanford in Section 3.1 includes the right to engage in Permitted Subcontracting, as defined herein.
“Permitted Subcontracting” shall include the grant by Fate, its Affiliate, or sublicensee of rights under this Agreement to (i) third parties contractually bound to Fate, an Affiliate or sublicensee for the sole purpose of marketing
or promoting a Licensed Product, (ii) third party contract research organizations contractually bound to Fate, an Affiliate or sublicensee with no other rights under Licensed Patents other than to perform research and development on behalf of
Fate, an Affiliate or sublicensee; and (iii) third party contract manufacturing organizations contractually bound to Fate, an Affiliate or sublicensee with no other rights under Licensed Patents than to manufacture on behalf of Fate, an
Affiliate or sublicensee. For clarity, Permitted Subcontracting is not considered sublicensing of rights under this Agreement. 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  
  

Page: 7 of 34 

	 	5	GOVERNMENT RIGHTS 

 In the
event that this Agreement is subject to Title 35 Sections 200-204 of the United States Code., these provisions (i) provide the United States Government with nonexclusive rights in the Licensed Patent; and (ii) impose the obligation that
Licensed Product sold or produced in the United States be “manufactured substantially in the United States.” If such provisions are applicable to this Agreement, Fate will ensure all obligations of these provisions are met. 

 

	 	6	DILIGENCE 

  

	 	6.1	Milestones. Because the invention is not yet commercially viable as of the Effective Date, Fate will use commercially reasonable efforts to develop, manufacture,
and commercialize at least one Licensed Product and will use commercially reasonable efforts to develop markets for such Licensed Product. In addition, Fate will use commercially reasonable efforts to meet the milestones shown in Appendix A, and
notify Stanford in writing after each milestone is met. 

  

	 	6.2	Missed Milestone. In the event that [***] at least one Licensed Product and [***], Stanford and Fate agree to [***]. The parties will cooperate and use good
faith efforts to [***]. Notwithstanding anything to the contrary in Article 16, Fate and Stanford acknowledge that termination of this Agreement under Section 16.3(A)(3) is a remedy of last resort. 

 

	 	6.3	Progress Report. By October 1 of each year, Fate will submit a written annual report to Stanford covering the preceding calendar year. The report will
include information sufficient to enable Stanford to satisfy reporting requirements of the U.S. Government, as applicable, and for Stanford to ascertain progress by Fate toward meeting this Agreement’s diligence requirements. Each report will
describe, where relevant: Fate’s progress toward commercialization of a Licensed Product, including work completed, key scientific discoveries, summary of work-in-progress, current schedule of anticipated events or milestones, market plans for
introduction of a Licensed Product, and significant corporate transactions involving a Licensed Product. 

  

	 	6.4	Clinical Trial Notice. Fate will notify Stanford prior to commencing any clinical trials at Stanford. 

 

	 	7	ROYALTIES 

  

	 	7.1	Issue Royalty. Fate will pay to Stanford a one-time, non-creditable, non-refundable license issue royalty of forty thousand dollars ($40,000) upon signing this
Agreement; provided, however that the payment of ten thousand dollars ($10,000) paid by Fate under the Exclusive License Term Sheet between the parties effective October 5 2012 shall be credited against the license issue royalty due
under this Agreement. 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  
  

Page: 8 of 34 

	 	7.2	Equity Interest. As further consideration, and subject to compliance with federal and state securities laws and other applicable laws, Fate will issue to
Stanford 50,000 shares of common stock in Fate pursuant to the terms and conditions of the Stock Purchase Agreement attached hereto as Appendix B to be executed by the parties concurrently herewith. Fate will issue 28.34 % of all shares granted
to Stanford pursuant to this Section 7.2 directly to and in the name of the inventors of the Licensed Patents listed below allocated as stated below: 

 Christopher Garcia – [***] 
 Aron Levin – [***]

  

	 	7.3	Repurchase Obligation. If Stanford is to conduct any clinical trial relating to the Licensed Patents on behalf of Fate or any agent of Fate, Fate upon request by
Stanford, will repurchase all Stanford’s equity interest in Fate. In such case, Fate cannot begin any such trial until Stanford no longer holds any equity interest in Fate. The repurchase price for any such equity interest will be the fair
market value for that equity at the time Fate and Stanford enter into a definitive agreement under which any such clinical research will be performed. Fair market value of publicly traded equity instruments will be determined by taking the average
of the closing price for such equity over the thirty (30) days preceding such date. To establish fair market value of non-public equity instruments, the parties will rely on a third-party valuation expert proposed by Fate and reasonably
acceptable to Stanford, where it is acknowledged that such third-party valuation expert shall use standard valuation methodologies for not publicly traded securities that are commonly accepted in the accounting industry. 

 

	 	7.4	License Maintenance Fee. On the first and second anniversaries of the Effective Date, Fate will pay Stanford a yearly license maintenance fee of [***] dollars
($[***]). On the third and fourth anniversaries of the Effective Date, Fate will pay Stanford a yearly license maintenance fee of [***] dollars ($[***]). On the fifth anniversary of the Effective Date, Fate will pay Stanford a yearly license
maintenance fee of [***] dollars ($[***]). Fate will pay Stanford [***] dollars ($[***]) on each anniversary thereafter. After the first commercial sale of a Licensed Product, such amount shall be fully creditable against Earned Royalties for that
year. 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  
  

Page: 9 of 34 

	 	7.5	Milestone Payments. Fate will pay Stanford the following milestone payments: 

 

	 	(A)	[***] dollars ($[***]) upon first US patent issuance, where the [***], under Licensed Patents; 

 

	 	(B)	[***] dollars ($[***]) upon [***] (payable once only); 

  

	 	(C)	[***] dollars ($[***]) upon [***] (payable once only); 

  

	 	(D)	[***] dollars ($[***]) upon [***] (payable once only); and 

  

	 	(E)	[***] dollars ($[***]) upon [***] (payable once only). 

  

	 	7.6	Earned Royalty. Subject to the terms of this Agreement, Fate will pay Stanford earned royalties on a country-by-country basis on Net Sales in countries where the
Licensed Product is covered by a Valid Claim. Fate will pay earned royalties of (a) [***] percent ([***]%) on Net Sales of a Licensed Product by Fate, its affiliates and/or sublicensees, [***] under the Licensed Patents; and (b) [***]
percent ([***]%) on Net Sales of a Licensed Product by Fate, its affiliates and/or sublicensees, where the Licensed Product [***] under Licensed Patents. 

  

	 	7.7	Royalty Stacking. In the event that Fate incurs royalty or other payment obligations to any third party in order to develop, make, have made, use, have used,
sell, have sold, offer for sale, have offered for sale, lease, have leased, import or have imported a Licensed Product within the Licensed Field of Use, then Fate can offset as a credit against earned royalty payable to Stanford under
Section 7.6 on Net Sales of such Licensed Product, [***] percent ([***]%) of the amount actually paid to such third parties for sales of Licensed Product; provided, however, that in no event will the earned royalty payable to Stanford under
Section 7.6 for Net Sales be reduced by more than [***] percent ([***]%). 

  

	 	7.8	Earned Royalty if Fate Challenges the Patent. Notwithstanding the above, should Fate bring any court action seeking to invalidate any Licensed Patent, Fate will
pay royalties to Stanford at [***] as set forth in Section 7.6 during the pendency of such action. Moreover, should the outcome of such action determine that any claim of a patent challenged by Fate is both valid and infringed by a Licensed
Product, Fate will [***] as set forth in Section 7.6 thereafter. 

  

	 	7.9	Creditable Payments. The license maintenance fee for a year may be offset against earned royalty payments due on Net Sales occurring in that year.

 For example: 
  

	 	(A)	if Fate pays Stanford a $10 maintenance payment for year Y, and according to Section 7.6 $15 in earned royalties are due Stanford for Net Sales in year Y, Fate
will only need to pay Stanford an additional $5 for that year’s earned royalties. 

  

	 	(B)	 if Fate pays Stanford a $10 maintenance payment for year Y, and according to Section 7.6 $3 in earned royalties are due Stanford for Net Sales in
year 

  
  

	* 	 Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  
  

Page: 10 of 34 

	 	
Y, Fate will not need to pay Stanford any earned royalty payment for that year. Fate will not be able to offset the remaining $7 against a future year’s earned royalties.

  

	 	7.10	Obligation to Pay Royalties. A royalty is due Stanford under this Agreement for any activity conducted under the licenses granted. For convenience’s sake,
the amount of that royalty is calculated using Net Sales. Nonetheless, solely in the event that certain Licensed Products are made or imported, but not sold, before the date this Agreement terminates, and such Licensed Products are then sold after
the termination date, Fate will pay Stanford an earned royalty for its exercise of rights based on the Net Sales of such made or imported Licensed Products. 

 

	 	7.11	No Escrow. Fate shall not pay royalties into any escrow or other similar account. 

 

	 	7.12	Currency. Fate will calculate the royalty on sales in currencies other than U.S. Dollars using the appropriate foreign exchange rate for the currency quoted by
the Wall Street Journal on the close of business on the last banking day of each calendar quarter. Fate will make royalty payments to Stanford in U.S. Dollars. 

 

	 	7.13	Non-U.S. Taxes. Fate will pay all non-U.S. taxes related to royalty payments. These payments are not deductible from any payments due to Stanford.

  

	 	7.14	Interest. Any payments not made when due will bear interest at the lower of (a) the [***] or (b) the maximum rate permitted by law.

  

	 	8	ROYALTY REPORTS, PAYMENTS, AND ACCOUNTING 

  

	 	8.1	Quarterly Earned Royalty Payment and Report. Beginning with the first commercial sale of a Licensed Product to a Customer, Fate will submit to Stanford a written
report (even if there are no commercial sales during such calendar quarter) and an earned royalty payment within forty-five (45) days after the end of each calendar quarter. This report will be in the form of Appendix C and will state the
number, description, and aggregate Net Sales of Licensed Product during the completed calendar quarter. With each report Fate will include any earned royalty payment due Stanford for the completed calendar quarter (as calculated under
Section 7.6 and subject to Section 7.9). 

  

	 	8.2	No Refund. In the event that a validity or non-infringement challenge of a Licensed Patent brought by Fate is successful, Fate will have no right to recoup any
royalties paid before or during the period challenge. 

  

	 	8.3	Termination Report. Fate will pay to Stanford all applicable royalties and submit to Stanford a written report within ninety (90) days after the license
terminates. Fate will continue to submit earned royalty payments and reports to Stanford after the license terminates, until all Licensed Products made or imported under the license prior to its termination have been sold. 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  
  

Page: 11 of 34 

	 	8.4	Accounting. Fate will maintain records showing manufacture, importation, sale, and use of a Licensed Product for three (3) years from the date of sale of
that Licensed Product, or for such longer period as is required by law. Records will include general-ledger records showing cash receipts and expenses, and records that include: production records, customers, invoices, serial numbers, and related
information in sufficient detail to enable Stanford to determine the royalties payable under this Agreement. 

  

	 	8.5	Audit by Stanford. Upon at least fifteen (15) business days’ advance written notice to Fate by Stanford, Fate will allow Stanford or its designee to
examine Fate’s records to verify payments made by Fate under this Agreement. Such examination shall not be made more than once each calendar year. 

  

	 	8.6	Paying for Audit. Stanford will pay for any audit done under Section 8.5. But if the audit reveals an underreporting of earned royalties due Stanford of
[***] percent ([***]%) or more for the period being audited, Fate will reimburse Stanford for the audit costs. 

  

	 	9	EXCLUSIONS AND NEGATION OF WARRANTIES 

  

	 	9.1	As of the Effective Date, Stanford represents that it has received the assignment rights from Kenan Christopher Garcia and Aron Levin to the Licensed Patents.

  

	 	9.2	Negation of Warranties. Except as noted in Section 9.1, Stanford provides Fate the rights granted in this Agreement AS IS and WITH ALL FAULTS. Stanford
makes no representations and extends no warranties of any kind, either express or implied. Among other things, Stanford disclaims any express or implied warranty: 

 

	 	(A)	of merchantability, of fitness for a particular purpose, 

  

	 	(B)	of non-infringement or 

  

	 	(C)	arising out of any course of dealing. 

  

	 	9.3	No Representation of Licensed Patent. Fate also acknowledges that Stanford does not represent or warrant: 

 

	 	(A)	the validity or scope of any Licensed Patent, or 

  

	 	(B)	that the exploitation of Licensed Patent will be successful. 

  

	 	10	INDEMNITY 

  

	 	10.1	Indemnification. 

  

	 	(A)	 Fate will indemnify, hold harmless, and defend all Stanford Indemnitees against any third party claim of any kind arising out of or related to the
practice of the Licensed Patents by Fate under this Agreement or the 

  
  

	* 	 Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  
  

Page: 12 of 34 

	 	
material breach of this Agreement by Fate, except to the extent that such third party claims are attributable to the gross negligence or willful misconduct of any of the Stanford Indemnitees.

  

	 	(B)	HHMI Indemnitees will be indemnified, defended by counsel acceptable to HHMI, and held harmless by Company from and against any claim, liability, cost, expense, damage,
deficiency, loss, or obligation, of any kind or nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) (collectively, “Claims”), based upon, arising out of, or otherwise relating to
this Agreement, including without limitation any cause of action relating to product liability. The previous sentence will not apply to any Claim that is determined with finality by a court of competent jurisdiction to result solely from the gross
negligence or willful misconduct of an HHMI Indemnitee. 

  

	 	10.2	No Indirect Liability. Neither party is liable to the other for any indirect, special, consequential or other damages whatsoever, whether grounded in tort
(including negligence), strict liability, contract or otherwise arising out of or in connection with solely this Agreement under any theory of liability, provided, however, that the foregoing will not apply to any right of action for infringement,
contributory infringement or inducement of infringement Stanford may have under any applicable law. Stanford will not have any responsibilities or liabilities whatsoever with respect to Licensed Products. 

 

	 	10.3	Workers’ Compensation. Fate will comply with all statutory workers’ compensation and employers’ liability requirements for activities performed
under this Agreement. 

  

	 	10.4	Insurance. Upon initiation of human clinical trials, Fate will maintain Comprehensive General Liability Insurance, including Product Liability Insurance, with a
reputable and financially secure insurance carrier to cover the activities of Fate and its sublicensees. The insurance will provide minimum limits of liability of [***] dollars ($[***]) and will include all Stanford Indemnitees and HHMI Indemnitees
as additional insureds. Insurance must cover claims incurred, discovered, manifested, or made during or after the expiration of this Agreement and must be placed with carriers with ratings of at least A- as rated by A.M. Best. Within fifteen
(15) days of any request by Stanford, Fate will furnish a Certificate of Insurance evidencing primary coverage and additional insured requirements. Fate will provide to Stanford thirty (30) days prior written notice of cancellation or
material change to this insurance coverage. All insurance of Fate will be primary coverage; insurance of Stanford Indemnitees and HHMI Indemnities will be excess and noncontributory. 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  
  

Page: 13 of 34 

	 	11	EXPORT 

 Fate warrants
that Fate will not export or re-export the following, directly or indirectly, to any country, individual or entity except when such export or re-export is authorized in full compliance with the laws and regulations of the United States of America,
as applicable: 
  

	 	(A)	the licensed technology or software, or any portion thereof, or 

  

	 	(B)	any foreign produced direct product (including equipment, processes or services) of the licensed technology or software; or 

 

	 	(C)	any foreign produced direct product of a plant or major component of a plant if the direct product of the licensed technology is the plant itself or a major component
of the plant. 

 Applicable laws and regulations may include, but are not limited to, the Export Administration
Regulations, the International Traffic in Arms Regulations and the various economic sanctions regulations administered by the U.S Department of the Treasury. 
  

	 	12	MARKING 

 Before any
Licensed Patent issues, Fate will mark a Licensed Product with the words “Patent Pending.” Otherwise, Fate will mark a Licensed Product with the number of any issued Licensed Patent. 

 

	 	13	STANFORD NAMES AND MARKS 

Fate will not identify Stanford or HHMI in any promotional statement, or otherwise use the name of any Stanford or HHMI faculty member,
employee, or student, or any trademark, service mark, trade name, or symbol of Stanford or Stanford Hospitals and Clinics or HHMI, including the Stanford or HHMI name, unless Fate has received Stanford’s or HHMI’s prior written consent.
Permission may be withheld at Stanford’s or HHMI’s sole discretion. Notwithstanding the foregoing, without the consent of Stanford, Fate may state to its actual and prospective investors, strategic partners and sublicensees that it is
licensed under the Licensed Patents and identify the inventors, their affiliation with Stanford and their relationship with Fate (if any), and further Fate may comply with disclosure requirements of all applicable laws relating to its business,
including, without limitation, United States and state securities laws. 
  

	 	14	PROSECUTION AND PROTECTION OF PATENTS 

  

	 	14.1	 Patent Prosecution. Following the Effective Date, Fate will be responsible for preparing, filing, and prosecuting the Licensed Patents
(including any interference or re-examination actions) in the Licensed Territory and for maintaining all Licensed Patents using counsel that is reasonably acceptable to both parties, in cooperation and with reasonable advance consultation and input
from Stanford. Fate will notify Stanford before taking any substantive actions in prosecuting the claims, and Stanford will provide information, execute and deliver documents and

  
  

Page: 14 of 34 

	 	
do other acts as Fate shall reasonably request from time to time. Fate will reimburse Stanford for Stanford’s reasonable costs incurred in complying with such requests. Stanford and Fate
agree to the terms detailed in Appendix D and agree to have Appendix D fully executed by the appropriate parties upon execution of this Agreement. Fate may terminate its obligations with respect to any given patent application or patent by providing
written notice of such termination at least thirty (30) days before any deadline for taking action to avoid abandonment (or other loss of rights). Commencing on the effective date of the notice to Stanford, Fate shall have no further right or
licenses hereunder to such patent application or patent in such country(ies). 

  

	 	14.2	Patent Costs. Within thirty (30) days after receiving a statement from Stanford, Fate will reimburse Stanford: 

 

	 	(A)	for all Licensed Patent’s patenting expenses, including any interference or re-examination matters, incurred by Stanford in prosecuting the Licensed Patents before
the Effective Date that have not been previously reimbursed to Stanford; and 

  

	 	(B)	for all Licensed Patent’s patenting expenses, including any interference or re-examination matters, incurred by Stanford after the Effective Date.

  

	 	14.3	Infringement Procedure. If a party to this Agreement learns of any potential infringement of a Licensed Patent, within sixty (60) days that party will
deliver written notice of the possible infringement to the other party, describing in detail the information suggesting such infringement of the Licensed Patent. During the Term of this Agreement and if Fate is actively pursuing development or
commercialization of a Licensed Product, Fate may have the right to institute a suit against this third party as provided in Sections 14.4 – 14.8. 

  

	 	14.4	Fate Suit. Fate has the first right, but not the obligation, to respond to, settle, defend and prosecute in its own name and at its own expense, legal actions or
suits relating to the Licensed Patents so long as it conforms with the requirements of this Section. Fate will use commercially reasonable efforts in pursuing the suit and Fate will bear the entire cost of any such litigation or settlement,
including reasonable expenses and counsel fees incurred by Stanford in connection with the litigation and settlement. Stanford agrees to provide reasonable assistance as requested by Fate including, without limitation, joining such action as a party
plaintiff if necessary or desirable for initiation or continuation of such action, provided that Stanford is not the first named party in the action. Fate will keep Stanford reasonably apprised of all developments in the suit, and will seek
Stanford’s reasonable input and approval on any substantive submissions or positions taken in the litigation regarding the scope, validity and enforceability of the Licensed Patent. Fate will not prosecute, settle or otherwise compromise any
such suit in a manner that adversely affects Stanford’s interests without Stanford’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. 

  
  

Page: 15 of 34 

	 	14.5	Recovery. If Fate institutes suit or enters into any settlement under Section 14.4, then any recovery in excess of any unrecovered litigation and settlement
costs and fees will be shared with Stanford as follows: 

 (A) any payment for past sales will be deemed Net Sales,
and Fate will pay Stanford royalties at the rates specified in Section 7.6; 
 (B) any payment for future sales will be
deemed a payment under a sublicense, and such payment will be shared as specified in Section 4.6. 
 (C) Fate and Stanford
will negotiate in good faith appropriate compensation to Stanford for any non-cash settlement or non-cash cross-license. 
  

	 	14.6	Joint Suit. If Stanford and Fate so agree, they may institute suit jointly. If so, they will: 

 

	 	(A)	prosecute the suit in both their names; 

  

	 	(B)	bear the out-of-pocket costs equally; 

  

	 	(C)	share any recovery or settlement equally; and 

  

	 	(D)	agree how they will exercise control over the action. 

  

	 	14.7	Stanford Suit. If Fate does not institute suit against an alleged infringer within six (6) months of receiving written notice of the possible infringement,
Stanford may institute suit after notifying Fate in writing at least thirty (30) days before filing any action. Stanford will bear the entire cost of the litigation, including reasonable expenses and counsel fees incurred by Fate in connection
with the litigation. Fate agrees to provide reasonable assistance as requested by Stanford including, without limitation, joining such action as a party plaintiff if necessary or desirable for initiation or continuation of such action. Stanford will
keep Fate reasonably apprised of all developments in the suit, and will seek Fate’s reasonable input and approval on any substantive submissions or positions taken in the litigation regarding the scope, validity and enforceability of the
Licensed Patent. Stanford will not prosecute, settle or otherwise compromise any such suit in a manner that adversely affects Fate’s interests without Fate’s prior written consent, which consent shall not be unreasonably withheld,
conditioned or delayed. 

  

	 	14.8	Abandonment of Suit. If either Stanford or Fate commences a suit and then wants to abandon the suit, it will give timely notice to the other party. The other
party may continue prosecution of the suit after Stanford and Fate agree on the sharing of expenses and any recovery in the suit. 

  

	 	15	CONFIDENTIALITY AND PUBLICATION 

  

	 	15.1	 Treatment of Confidential Information. Stanford and Fate agree that during the Term of this Agreement, and for a period of five (5) years
after this Agreement terminates, a party receiving Confidential Information of the other party will (a) maintain in confidence such Confidential Information to the same extent such party maintains its own proprietary information; (b) not
disclose such Confidential Information to 

  
  

Page: 16 of 34 

	 	
any third party without prior written consent of the other party; and (c) not use such Confidential Information for any purpose except those permitted by this Agreement. Notwithstanding the
foregoing, if a party is required by law, regulation or court order to disclose Confidential Information of the other party, the party required to make such disclosure shall (i) promptly send a copy of the order or notice to the other party not
later than ten (10) days before the proposed disclosure or such shorter period of time as may be reasonably practical under the circumstances; (ii) cooperate with the other party if the other party wishes to object or condition such
disclosure through a protective order or otherwise; (iii) limit the extent of such disclosure to the minimum required to comply with the order or notice; and (iv) use reasonable efforts to seek confidential treatment (i.e., filing
“under seal”) for that disclosure. In addition, a party may disclose Confidential Information of the other party to its Affiliates and employees, to sublicensees and potential sublicensees (in the case of Fate), or to other third parties
who are investors or potential investors in connection with due diligence or similar investigations or in confidential financing documents, provided, in each case, that any such Affiliate, employee, sublicensee, potential sublicensee or other third
party investor or potential investor agrees to be bound by terms of confidentiality and non-use no less stringent than those set forth in this Section 15. 

 

	 	16	TERM; TERMINATION 

  

	 	16.1	Term. Unless otherwise terminated by operation of law or by the parties in accordance with the terms and conditions of this Agreement, the term of this Agreement
(the “Term”) shall commence on, and this Agreement shall be in force from, the Effective Date and remain in effect on a country-by-country basis until the last-to-expire or last to be abandoned claim of any Licensed Patent, whichever is
later, licensed under this Agreement in such country (the “Patent Expiration Date”). After the Patent Expiration Date, the license granted in Article 3 shall become fully paid-up, royalty-free, perpetual and irrevocable in such country,
subject to Section 7.10. 

  

	 	16.2	Termination by Fate. Fate may terminate this Agreement by giving Stanford written notice at least thirty (30) days in advance of the effective date of
termination selected by Fate. 

  

	 	16.3	Termination by Stanford. 

  

	 	(A)	Stanford may terminate this Agreement if Fate: 

  

	 	(1)	is delinquent on any report or payment; 

  

	 	(2)	is not actively pursuing development or commercialization of Licensed Product; 

 

	 	(3)	misses a milestone described in Appendix A, provided that termination under this Section 16.3(A)(3) is subject to the provisions of Section 6.2;

  

	 	(4)	is in material breach of any provision of this Agreement; or 

  

	 	(5)	provides any false report. 

  

	 	(B)	Termination under this Section 16.3 will take effect sixty (60) days after written notice by Stanford unless Fate remedies the problem in that sixty
(60) day period. 

  
  

Page: 17 of 34 

	 	16.4	Surviving Provisions. Surviving any termination or expiration are: 

  

	 	(A)	Fate’s obligation to pay royalties accrued or accruable; 

  

	 	(B)	any claim of Fate or Stanford, accrued or to accrue, because of any breach or default by the other party; and 

 

	 	(C)	the provisions of Articles 8, 9, 10, 15 and 20.5 and any other provision that by its nature is intended to survive. 

 

	 	16.5	Effect of Termination on Sublicensees. If this Agreement is terminated for any reason, all outstanding sublicenses not in default will be assigned by Fate to
Stanford (but not other non-sublicense contract elements). The assigned sublicenses will remain in full force and effect with Stanford as the licensor instead of Fate. 

 

	 	16.6	Inventory. Upon termination of this Agreement prior to its expiration, Fate shall have the right to dispose of all previously made or partially made Licensed
Products, provided that Fate submits royalty reports on the sale of such Licensed Products and pays the earned royalty as required under this Agreement. 

  

	 	17	ASSIGNMENT 

  

	 	17.1	Permitted Assignment by Fate. Subject to Section 17.3, Fate may assign this Agreement as part of a sale, regardless of whether such a sale occurs through an
asset sale, stock sale, merger, reorganization, consolidation or other combination, or any other transfer of: 

  

	 	(A)	Fate’s entire business; or 

  

	 	(B)	that part of Fate’s business that exercises all rights granted under this Agreement. 

 

	 	17.2	Any Other Assignment by Fate. Any other attempt to assign this Agreement by Fate is null and void. 

 

	 	17.3	Conditions of Assignment. Prior to any assignment, the following conditions must be met: 

 

	 	(A)	Fate must give Stanford written notice of the assignment, including the new assignee’s contact information, within thirty (30) days of the assignment; and

  

	 	(B)	the new assignee must agree in writing to Stanford to be bound by this Agreement; and 

  
  

Page: 18 of 34 

	 	(C)	Stanford must have received a [***] dollar assignment fee ($[***]) except that an assignment fee under this Section 17.3 will not apply and will not be payable
upon an assignment of this Agreement to an affiliate, or in connection with an acquisition of the assets or sale of Fate related to this Agreement. 

  

	 	17.4	After the Assignment. Upon a permitted assignment of this Agreement pursuant to Article 17, Fate will be released of liability under this Agreement and the term
“Fate” in this Agreement will mean the assignee. Subject to the foregoing, this Agreement in binding upon and inures to the benefit of Fate and its permitted successors and assigns. 

 

	 	18	ARBITRATION 

  

	 	18.1	Dispute Resolution. Except as otherwise provided herein, any dispute between the parties arising out of or relating to this Agreement will be settled by
arbitration in accordance with the Licensing Agreement Arbitration Rules of the American Arbitration Association. The parties are not obligated to settle by arbitration any dispute relating to the validity of the Licensed Patents. Notwithstanding
the foregoing, no dispute affecting the rights or property of HHMI shall be subject to the arbitration provisions set forth in this Article 18. 

  

	 	18.2	Request for Arbitration. Either party may request such arbitration. Stanford and Fate will mutually agree in writing on a third party arbitrator within thirty
(30) days of the arbitration request. The arbitrator’s decision will be final and non-appealable and may be entered in any court having jurisdiction. 

 

	 	18.3	Discovery. The parties will be entitled to discovery as if the arbitration were a civil suit in the California Superior Court. The arbitrator may limit the
scope, time, and issues involved in discovery. 

  

	 	18.4	Place of Arbitration. The arbitration will be held in Stanford, California unless the parties mutually agree in writing to another place.

  

	 	18.5	Patent Validity. Any dispute between Stanford and Fate, or Stanford and a sublicensee of Fate, regarding the validity of any Licensed Patent shall be litigated
in the courts located in Santa Clara County, California, and the parties agree not to challenge personal jurisdiction in that forum. 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  
  

Page: 19 of 34 

	 	19	NOTICES 

  

	 	19.1	Legal Action. Fate will provide written notice to Stanford at least three months prior to bringing an action seeking to invalidate any Licensed Patent or a
declaration of non-infringement. Fate will include with such written notice an identification of all prior art it believes invalidates any claim of the patent. 

 

	 	19.2	All Notices. All notices under this Agreement are deemed fully given when written, addressed, and sent as follows: 

All general notices to Fate are mailed to: 
 Fate Therapeutics, Inc. 
 Attn: CFO 

3535 General Atomics Court, Suite 200 
 San Diego, CA 92121 
 All financial invoices to Fate (i.e., accounting contact) are
e-mailed to: 
 accounting@fatetherapeutics.com 
 Attn: Jessica Francis 
 3535 General Atomics Court, Suite 200 

San Diego, CA 92121 
 All progress report invoices to Fate (i.e., technical contact) are e-mailed to: 

accounting@fatetherapeutics.com 
 Attn: Jessica Francis 
 3535 General Atomics Court, Suite 200 

San Diego, CA 92121 
 All general notices to Stanford are e-mailed or mailed to: 
 Office of Technology
Licensing 
 1705 El Camino Real 
 Palo Alto, CA 94306-1106 
 info@otlmail.stanford.edu 

  
  

Page: 20 of 34 

 All payments to Stanford are mailed to: 

Stanford University 
 Office of Technology Licensing 
 Department #44439 

P.O. Box 44000 

San Francisco, CA 94144-4439 
 All progress reports to Stanford are e-mailed or mailed to: 
 Office of Technology
Licensing 
 1705 El Camino Real 
 Palo Alto, CA 94306-1106 
 info@otlmail.stanford.edu 

Either party may change its address with written notice to the other party. 

 

	 	20	MISCELLANEOUS 

  

	 	20.1	Waiver. No term of this Agreement can be waived except by the written consent of the party waiving compliance. 

 

	 	20.2	Choice of Law. This Agreement and any dispute arising under it is governed by the laws of the State of California, United States of America, applicable to
agreements negotiated, executed, and performed within California without reference to its conflicts of laws principles. 

  

	 	20.3	Exclusive Forum. The state and federal courts having jurisdiction over Stanford, California, United States of America, provide the exclusive forum for any court
action between the parties relating to this Agreement. The parties submit to the jurisdiction of such courts, and waive any claim that such a court lacks jurisdiction over the parties or constitutes an inconvenient or improper forum.

  

	 	20.4	Headings. No headings in this Agreement affect its interpretation. 

  

	 	20.5	Third Party Beneficiary. HHMI is not a party to this Agreement and has no liability to any licensee, sublicensee or user of any technology covered by this
Agreement, but HHMI is an intended third-party beneficiary of this Agreement and certain of its provisions are for the benefit of HHMI and are enforceable by HHMI in its own name. 

 

	 	20.6	Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for
which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. 

  
  

Page: 21 of 34 

 The parties execute this Agreement in duplicate originals by their duly authorized officers
or representatives. 
  

									
		 	THE BOARD OF TRUSTEES OF THE LELAND	 	
			
		 	STANFORD JUNIOR UNIVERSITY	 	
					
		 		 	Signature	 	/s/ Luis Mejia	 	
					
		 		 	Name	 	Luis Mejia	 	
					
		 		 	Title	 	Acting Director, Office of Technology Licensing	 	
					
		 		 	Date	 	13 May 2013	 	
			
		 	Fate Therapeutics, Inc.	 	
					
		 		 	Signature	 	/s/ Scott Wolchko	 	
					
		 		 	Name	 	Scott Wolchko	 	
					
		 		 	Title	 	CFO	 	
					
		 		 	Date	 	2 May 2013	 	

  
  

Page: 22 of 34 

 APPENDIX A 
 Subject to Fate’s right to extend the timeline for one or more diligence milestone events, as set forth below, Fate shall itself use, or shall cause its Affiliates or sublicensees, as applicable, to
use commercially reasonable efforts to diligently proceed to develop and make commercially available at least one License Product in the Licensed Field of Use, consistent with sound and reasonable business practice and judgment, and in accordance
with the following: 
 [***] 
 Notwithstanding anything to the contrary in this Appendix A, if Fate, its Affiliates or its sublicensees should experience any delay which is caused (in whole or in part) (a) by any requirement by
the FDA to generate and/or provide carcinogenicity or other safety data regarding such Licensed Product, or (b) any requirement by the FDA to repeat any clinical trial regarding such Licensed Product, or (c) by the FDA, where such delay
was not the result of Fate, its Affiliate’s or its sublicensee’s (i) actions; (ii) failure to abide by FDA instructions; and/or (iii) failure to provide data to the FDA in a form and in an amount consistent with best
practices in the industry, then the timeline for all milestone events not yet achieved shall be extended for a period which is equal to the period of such delay. 
 Notwithstanding anything to the contrary in the Agreement, in the event that Fate is unable to achieve a given diligence milestone according to the applicable timeline as set forth above, Fate may, [***]
under the Agreement, extend the timeline by [***] by making a [***] Dollar ($[***]) payment to Stanford (where, for the avoidance of doubt, all later occurring diligence milestone(s) shall also be similarly extended by [***]). 

 

	*	 Confidential
Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission. 

  
  

Page: 23 of 34 

 APPENDIX B 
 STOCK PURCHASE AGREEMENT 
 THIS STOCK PURCHASE AGREEMENT
(this “Agreement”) is entered into as of the 2nd day of May, 2013, by and between Fate Therapeutics, Inc., a Delaware corporation (the “Corporation”), with its principal place of business located at 3535 General Atomics Court,
Suite 200, San Diego, CA 92121, and the Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“UNIVERSITY”). 

WHEREAS, UNIVERSITY and the Corporation have entered into an Exclusive Patent License Agreement effective as of the
2nd day of May, 2013 (the “License
Agreement”); 
 WHEREAS, pursuant to the License Agreement, the Corporation has agreed to issue to UNIVERSITY thirty
five thousand eight hundred thirty (35,830) shares (the “Shares”) of common stock, par value $0.001 per share, of the Corporation (the “Common Stock”) in accordance with the terms hereof; 

WHEREAS, UNIVERSITY has agreed to accept the Shares upon such terms; 

NOW, THEREFORE, in consideration of the mutual covenants herein contained and other valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereby agree as follows: 
 1. The Closing. The closing for the
transactions contemplated hereby (the “Closing”) shall take place at the offices of Goodwin Procter LLP, San Diego, California, on the date hereof or at such other time or location upon which the parties may mutually agree. The
Corporation shall issue to UNIVERSITY the Shares at the Closing in consideration for (1) UNIVERSITY’s execution and delivery of the License Agreement, and (2) payment by UNIVERSITY to the Corporation of an amount equal to the
aggregate par value of the Shares being purchased by UNIVERSITY hereunder. Promptly after the Closing, the Corporation shall deliver to UNIVERSITY a stock certificate, registered in the name of UNIVERSITY, which shall represent the Shares.

 2. Representations and Warranties of the Corporation. The Corporation hereby represents and warrants to UNIVERSITY at
the Closing as follows: 
 2.1 Organization. The Corporation is a corporation duly organized, validly existing and in
good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry out the transactions contemplated hereby. 
 2.2 Authorization of this Agreement. The execution, delivery and performance by the Corporation of this Agreement has been duly authorized by all requisite corporate action. This Agreement has been
duly executed and delivered on behalf of the Corporation and constitutes the valid and binding obligations of the Corporation, enforceable in 

  
  

Page: 24 of 34 

 
accordance with its terms. The execution, delivery and performance of this Agreement, and the issuance, sale and delivery of the Shares, and compliance with the provisions hereof and thereof by
the Corporation, do not and will not (i) violate any provision of law, statute, ordinance, rule or regulation or any ruling, writ, injunction, order, judgment or decree of any court, administrative agency or other governmental body, or
(ii) conflict with or result in any breach of any of the terms, conditions or provisions of, or constitute a default (or give rise to any right of termination, cancellation or acceleration) under, or result in the creation of any lien, security
interest, charge or encumbrance upon any of the properties or assets of the Corporation under, the Certificate of Incorporation or the Bylaws of the Corporation (as each may be amended and/or restated from time to time, the “Certificate of
Incorporation” and “Bylaws”, respectively). 
 2.3 Authorization of Shares. The issuance, sale
and delivery of the Shares by the Corporation hereunder have been duly authorized by all requisite corporate action of the Corporation, and when so issued, sold and delivered in accordance with the terms of this Agreement, the Shares will be validly
issued and outstanding, fully paid and nonassessable. 
 2.4 Exemptions from Securities Laws. Subject to the accuracy of
the representations and warranties of UNIVERSITY set forth in Section 3, the provisions of Section 5 of the Securities Act of 1933, as amended (the “Securities Act”) are inapplicable to the offering, issuance, sale and
delivery of the Shares by virtue of the exemption afforded by Section 4(2) of the Securities Act, and no consent, approval, qualification or registration or filing under any state securities or “Blue Sky” laws is required in
connection therewith, except for such filings which are required or permitted to be made after the Closing and which will be made on a timely basis by the Corporation. 
 3. Representations and Warranties of UNIVERSITY. UNIVERSITY hereby represents and warrants to the Corporation as of the Closing as follows. 

(a) UNIVERSITY is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization, has all
requisite power and authority and has taken all necessary action required for the due authorization, execution, delivery and performance of this Agreement. This Agreement has duly executed and delivered on behalf of UNIVERSITY and constitutes the
valid and binding obligations of UNIVERSITY, enforceable in accordance with its terms. 
 (b) UNIVERSITY has not been organized,
reorganized or recapitalized specifically for the purposes of investing in the Corporation, and UNIVERSITY is acquiring the Shares for investment and not for, with a view to, or in connection with the distribution thereof. 

(c) UNIVERSITY understands that the Shares have not been registered under the Securities Act or any state securities law by reason of
their issuance in a transaction exempt from the registration requirements of the Securities Act and such laws, and that the Shares must be held indefinitely unless the Shares are subsequently registered under the Securities Act and such laws or a
subsequent disposition thereof is exempt from registration. The certificates for the Shares shall bear a legend to such effect. 

  
  

Page: 25 of 34 

 (d) UNIVERSITY understands that the exemption from registration afforded by Rule 144
promulgated by the Securities and Exchange Commission under the Securities Act depends upon the satisfaction of various conditions and that, if applicable, Rule 144 affords the basis for sales only in limited amounts. 

(e) UNIVERSITY represents and warrants that it (i) has sufficient knowledge and experience in business and financial matters and
with respect to investment in securities of privately held companies so as to enable it to analyze and evaluate the merits and risks of the investment contemplated hereby, (ii) is able to bear the economic risk of such investment, and
(iii) is an “Accredited Investor” as defined in Rule 501(a) of Regulation D under the Securities Act. Further, UNIVERSITY is aware of the Corporation’s business affairs and condition and has acquired sufficient information
about the Corporation to reach an informed and knowledgeable decision to acquire the Shares. 
 (f) All negotiations relating to
this Agreement and the transactions contemplated hereby have been carried on without the intervention of any person acting on behalf of UNIVERSITY in such manner as to give rise to any right, interest or valid claim for any brokerage or
finder’s commission, fee or similar compensation. 
 4. Additional Agreements. 

4.1 Right of First Refusal. Before any Shares held by UNIVERSITY or any transferee of UNIVERSITY (either being referred to in this
Agreement as the “Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the Corporation or its assignee(s) shall have a right of first refusal to purchase the Shares on the terms and
conditions set forth in this Section 4.1 (the “Right of First Refusal”). 
 (a) Notice of Proposed
Transfer. The Holder of the Shares shall deliver to the Corporation a written notice (the “Notice”) stating: (A) the Holder’s bona fide intention to sell or otherwise transfer such Shares; (B) the name of
each proposed purchaser or other transferee (“Proposed Transferee”); (C) the number of Shares to be transferred to each Proposed Transferee; and (D) the terms and conditions of each proposed sale or transfer. The Holder
shall offer the Shares at the same price (the “Offered Price”) and upon the same terms (or terms as similar as reasonably possible) to the Corporation or its assignee(s). 

(b) Exercise of Right of First Refusal. At any time within 30 days after receipt of the Notice, the Corporation and/or its
assignee(s) may, by giving written notice to the Holder, elect to purchase all or any portion of the Shares proposed to be transferred to any one or more of the Proposed Transferees, at the purchase price determined in accordance with clause
(c) below. 
 (c) Purchase Price. The purchase price (“Purchase Price”) for the Shares purchased by
the Corporation or its assignee(s) under this Section 4.1 shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value of the non-cash consideration
shall be determined by the Board of Directors of the Corporation in good faith. 

  
  

Page: 26 of 34 

 (d) Payment. Payment of the Purchase Price shall be made, at the option of the
Corporation or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness, or by any combination thereof within 30 days after receipt of the Notice or in the manner and at the times set forth in the
Notice. 
 (e) Holder’s Right to Transfer. If all of the Shares proposed in the Notice to be transferred to a given
Proposed Transferee are not purchased by the Corporation and/or its assignee(s) as provided in this Section 4.1, then the Holder may sell or otherwise transfer such Shares to that Proposed Transferee at the Offered Price or at a higher price,
provided that such sale or other transfer is consummated within 60 days after the date of the Notice and provided further that any such sale or other transfer is effected in accordance with any applicable securities laws and the Proposed Transferee
agrees in writing that the provisions of this Section 3 shall continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not transferred to the Proposed Transferee within such period, or
if the Holder proposes to change the price or other terms to make them more favorable to the Proposed Transferee, a new Notice shall be given to the Corporation, and the Corporation and/or its assignees shall again be offered the Right of First
Refusal before any Shares held by the Holder may be sold or otherwise transferred. 
 (f) Assignment. The right of the
Corporation to purchase any part of the Shares may be assigned in whole or in part to any stockholder or stockholders of the Corporation or other persons or organizations. 
 (g) Restrictions Binding on Transferees. All Holders of Shares or any interest therein will receive and hold such Shares or interest subject to the provisions of this Agreement, including, insofar
as applicable, the Right of First Refusal. Any sale or transfer of the Shares shall be void unless the provisions of this Agreement are satisfied. 
 4.2 Bring-Along Transactions. UNIVERSITY hereby agrees to the following: 

(a) In the event of an Approved Transaction (as defined in that certain Amended and Restated Voting Agreement dated October 26,
2012, by and among the Corporation and the stockholders listed as parties thereto (a copy of which shall be provided to UNIVERSITY upon request), as the same may be amended and/or restated from time to time (the “Voting
Agreement”)), UNIVERSITY shall be bound by and, at the request of the Corporation, shall comply with all terms and conditions contained in Section 4 of the Voting Agreement to the same extent as the Founders (as defined in the Voting
Agreement) are bound thereunder. 
 (b) In addition to and notwithstanding the foregoing, in the event the holders of a majority
of the outstanding shares of equity securities of the Corporation (the “Majority Holders”) determine to sell or otherwise dispose of all or substantially all of the assets of the Corporation or all or fifty percent (50%) or
more of the capital stock of the Corporation, in each case in a transaction constituting a change in control of the Corporation, to any third party, or to cause the Corporation to merge with or into or consolidate with any third party (in each case,
the “Buyer”) in a bona fide negotiated transaction (a “Sale”), UNIVERSITY shall, at the request of the Corporation, (i) sell, transfer and deliver, or cause to be sold, transferred and delivered, to the
Buyer, UNIVERSITY’s Shares on substantially the same 

  
  

Page: 27 of 34 

 
terms applicable to the Majority Holders (with appropriate adjustments to reflect the conversion of convertible securities, the redemption of redeemable securities and the exercise of exercisable
securities as well as the relative preferences and priorities of preferred stock) and (ii) execute and deliver such instruments of conveyance and transfer and take such other action, including voting such Shares in favor of any Sale proposed by
the Majority Holders and executing any purchase agreements, merger agreements, indemnity agreements, escrow agreements or related documents as the Majority Holders or the Buyer may reasonably require in order to carry out the terms and provisions of
this Section 4.2(b). 
 4.3 Market Standoff. UNIVERSITY agrees in connection with the Corporation’s first
public offering of Common Stock to the general public that is effected pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission under the Securities Act (“IPO”), upon request
of the underwriters managing such IPO, not to sell, make any short sale of, loan, pledge or otherwise hypothecate or encumber, grant any option for the purchase of, or otherwise dispose of any shares of capital stock of the Corporation, including
shares issuable upon exercise or conversion of Convertible Securities (other than those included in the registration) without the prior written consent of such underwriters, as the case may be, for such period of time (not to exceed 180 days, but
subject to extension(s) as may be required by the underwriters in order to publish research reports while complying with Rule 2711 of the National Association of Securities Dealers, Inc.) as may be requested by such managing underwriters; provided,
that all directors, officers and holders of one percent (1%) or more of the Corporation’s outstanding capital stock are similarly bound; and provided, further, that any early release of any then-current or former officer or director or any
holder of one percent (1%) or more of the Corporation’s outstanding capital stock from market standoff agreements similar to the foregoing is apportioned pro rata among all securityholders bound by such market standoff agreements.

 4.4 Termination of Rights. The provisions set forth in Sections 4.1 and 4.2 will terminate upon the earlier to occur
of (a) the first sale of Common Stock of the Corporation to the general public pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission under the Securities Act and (b) the completion
of a Liquidation (as defined in the Certificate of Incorporation). 
 5. Miscellaneous. 

5.1 Dispute Resolution. For resolution of any dispute arising in connection with this Agreement (each a
“Dispute”), the party raising the Dispute shall promptly notify the other party of such Dispute in writing describing in reasonable detail the nature of such Dispute. The parties shall attempt to resolve such Dispute through good
faith discussions and negotiation. If the parties are unable to resolve such Dispute within a thirty (30) day period, the Dispute shall be referred to Corporation’s Chief Executive Officer and UNIVERSITY’s Vice Provost for
Intellectual Property and Technology Transfer (the “Executives”) for resolution. The Executives shall attempt to resolve such Dispute through good faith discussion and negotiation. If the Executives fail to resolve such Dispute
within forty-five (45) days after the Dispute is referred to them, the parties may mutually agree to resolve such Dispute through other informal procedural means, including, but not limited to,

  
  

Page: 28 of 34 

 
referral to an independent, neutral third party expert, mediation, arbitration and/or any other procedure(s) upon which the parties mutually agree. Each party agrees that, prior to resorting to
litigation to resolve any Dispute, it will confer in good faith with the other party to determine whether other procedures that are less expensive or less time consuming can be adopted to resolve the Dispute. For the avoidance of doubt, in the event
of a bona fide Dispute (for example, a Dispute regarding the existence of a material breach), the period for a party’s performance in relation to such Dispute (for example, the cure of a disputed material breach), and all applicable statutes of
limitation and time-based defenses (for example, laches and estoppel), shall be tolled from the date of delivery of written notice of such Dispute until the date of resolution of such Dispute pursuant to this Section 5.1. 

5.2 Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, each of the parties hereto and each
other person or entity who shall become a registered holder named in any certificate evidencing shares of Common Stock transferred to such holder by UNIVERSITY or its transferees, and their respective heirs, legal representatives, successors and
assigns. 
 5.3 Entire Agreement; Effect on Prior Documents. This Agreement and the other documents referred to herein or
delivered pursuant hereto contain the entire agreement between the parties with respect to the financing transactions contemplated hereby and supersede all prior negotiations, commitments, agreements and understandings between them with respect
thereto. 
 5.4 Notices. Any notice or communication given by one party to the other in connection with this Agreement
shall be sufficiently given if given in accordance with the applicable provisions set forth in the License Agreement. 
 5.5
Amendments; Waivers. Except as otherwise provided herein, this Agreement may be amended, and compliance with any provision of this Agreement may be omitted or waived, only by the written agreement of the Corporation and the UNIVERSITY. A
waiver or omission on one occasion shall not constitute a waiver or omission on any further occasion. 
 5.6 Counterparts,
Facsimiles. This Agreement may be executed in any number of counterparts, each such counterpart shall be deemed to be an original instrument, and all such counterparts together shall constitute but one agreement. Facsimile transmission of
execution copies or signature pages for this Agreement shall be legal, valid and binding execution and delivery for all purposes. 
 5.7 Sections, Headings. Section references herein refer to sections of this Agreement unless expressly provided to the contrary. The headings of the various sections of this Agreement have been
inserted for convenience of reference only and shall not be deemed to be a part of this Agreement. 
 5.8 Governing Law.
This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of California, regardless of its conflict of laws provisions. 

  
  

Page: 29 of 34 

 5.9 Severability. Any provision of this Agreement that is prohibited or unenforceable
in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not
invalidate or render unenforceable such provision in any other jurisdiction. 
 IN WITNESS WHEREOF, the parties have executed
this Stock Purchase Agreement under seal as of the day and year first above written. 
  

							
	FATE THERAPEUTICS, INC.
				
	By:	 	/s/ Scott Wolchko	 		 	
				
	Name:	 	Scott Wolchko	 		 	
				
	Title:	 	CFO	 		 	
	
	BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
				
	By:	 	/s/ Katharine Ku	 		 	
				
	Name:	 	Katharine Ku	 		 	
				
	Title:	 	Director Technology Licensing	 		 	

  
  

Page: 30 of 34 

 APPENDIX C 
 SAMPLE REPORTING FORM 
 Stanford Docket No. 

This report is provided pursuant to the license Agreement between Stanford University and Fate Therapeutics. 

License Agreement Effective Date: 
 Name(s) of Licensed Product(s): 
  

					
	 Report Covering Period
	  			
	 Yearly Maintenance Fee
	  	$	        	  
	 Number of Sublicenses Executed
	  			
	 Gross Sales
	  	$	        	  
	 Net Sales
	  	$	        	  
	 Royalty Calculation
	  			
	 Royalty Subtotal
	  	$	        	  
	 Credit
	  	$	        	  
	 Royalty Due
	  	$	        	  

 Comments: 

  
  

Page: 31 of 34 

 APPENDIX D 
 CLIENT AND BILLING AGREEMENT 
 The Board of Trustees of the Leland Stanford
Junior University (“STANFORD”); and Fate Therapeutics, Inc., a Corporation of the State of Delaware, with a principal place of business at 3535 General Atomics Court, Sutie 200, San Diego, Ca 92121, (“COMPANY”); have agreed to
use the law firm of Cooley, LLP (“FIRM”) to prepare, file and prosecute the pending patent applications listed in Exhibit A attached hereto and maintain the patents that issue thereon (“Patents”). 

WHEREAS, FIRM desires to perform the legal services related to obtaining and maintaining the Patents; and 

WHEREAS, STANFORD remains the client of the FIRM; and 
 WHEREAS, COMPANY is the licensee of STANFORD’s interest in the Patents; 
 NOW
THEREFORE, in consideration of the premises and the faithful performance of the covenants herein contained, IT IS AGREED: 
 1.
FIRM can interact directly with COMPANY on all patent prosecution matters related to the Patents and will copy STANFORD on all correspondence. STANFORD will be notified by FIRM prior to any substantive actions and will have final approval on
proceeding with such actions; provided that Stanford’s actions regarding prosecution will promote the goal of obtaining the broadest patent coverage available with respect to the Patents, will be consistent with the goal of obtaining patents
that are valid and enforceable and will not be detrimental to the practice of the Patents by Fate. 
 2. COMPANY is responsible
for the payment of all charges and fees by FIRM related to the prosecution and maintenance of the Patents. FIRM will invoice COMPANY and must copy STANFORD on all invoices. COMPANY must pay FIRM directly for all charges. 

  
  

Page: 32 of 34 

 3. Notices and copies of all correspondence should be sent to the following: 

To COMPANY: 
 Scott Wolchko, CFO 
 Fate Therapeutics, Inc. 

3535 General Atomics Court, Suite 200 

San Diego, CA 92121 
 To STANFORD: 
 Name 

Office of Technology Licensing 
 Stanford University 
 1705 El Camino Real 

Palo Alto, CA 94306-1106 
 To FIRM: 
 Cooley LLP 

ATTN: William Christiansen, Ph.D., Esq. 

1700 Seventh Avenue, Suite 1900 
 Seattle, WA 98101-1355 
 4. The parties to this document agree that a copy of the
original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a
court of law based solely on the absence of an original signature. 

  
  

Page: 33 of 34 

 ACCEPTED AND AGREED TO: 

 

					
	STANFORD	  	
			
	By:	 	/s/ Katharine Ku	  	
			
	Name:	 	Katharine Ku	  	
			
	Title:	 	Director	  	
		
	FATE THERAPEUTICS, INC.	  	
			
	By:	 	/s/ Scott Wolchko	  	
			
	Name:	 	Scott Wolchko	  	
			
	Title:	 	CFO	  	
			
	Date:	 	7 May 2013	  	
		
	COOLEY LLP	  	
			
	By:	 	/s/ William T. Christiansen	  	
			
	Name:	 	William T. Christiansen	  	
			
	Title:	 	Partner	  	
			
	Date:	 	5/7/13	  	

  
  

Page: 34 of 34EX-10.11

 EXHIBIT 10.11 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 
 RESTATED LICENSE AGREEMENT 
 This Agreement made effective as of this
6th day of April, 2010 between: 

The Ottawa Hospital Research Institute, with a business address of 725 Parkdale Avenue Ottawa, Ontario, K1Y 4E9, Canada (hereinafter
“Licensor”) 
 and 
 Verio Therapeutics Inc., with a business address of 100 Queen Street, Ottawa, Ontario, K1P 1J9, Canada (hereinafter “Licensee”). 

BACKGROUND 
 WHEREAS the corporate
name of the Licensor was changed from the “Ottawa Health Research Institute” to “Ottawa Hospital Research Institute” by Supplementary Letters Patent dated March 19, 2009 under the Corporations Act of Ontario.

 WHEREAS Licensee is in the business of the development and commercial exploitation of technology potentially useful for protein and
small molecule therapies for the treatment or prevention of human diseases; 
 WHEREAS Licensor owns technologies relating to protein and
small molecule therapies for the treatment of diseases and has filed patent applications relating to said technologies and co-owns with Licensee certain patent applications relating thereto that may be useful to Licensee in the operation of its
business; 
 WHEREAS Licensor and Licensee may develop additional Co-Owned Technologies (as defined below) and patent applications;

 WHEREAS Licensor wishes to see the aforementioned Licensor owned or co-owned technologies commercially exploited to the benefit of the
Licensor, Licensee and ultimately the public through access to such technologies; 
 WHEREAS Licensor and Licensee
entered into that certain License Agreement with an effective date of December 22nd, 2008, as amended June 5, 2009 and September 1, 2009 (the “First License Agreement”), pursuant to which Licensor granted and Licensee obtained a license to
Licensor’s patent rights in and to the aforementioned Licensor and Co-Owned Technologies, as further described herein; 

  

			
		  	Page 1 of 26

 WHEREAS Licensor and Licensee now desire to execute this Restated License Agreement (the
“Agreement”) which, as of the Effective Date of this Agreement, shall supersede the First License Agreement, as amended, in its entirety. 
 NOW THEREFORE, in consideration of the foregoing premises, the mutual covenants and obligations hereinafter contained, and other good and valuable consideration, Licensor and Licensee agree as
follows. 
 ARTICLE 1 
 INTERPRETATION 
  

	1.1	Definitions 

 For the
purposes of this Agreement, the following capitalized terms, words, and phrases, when used in either the singular or plural, shall have the following meanings. 

“Affiliate” means, with respect to a party to this Agreement, any Entity which controls, is controlled
by, or is under common control with such party, where the term “control” means direct or indirect possession of at least forty percent (40%) of the voting securities or comparable equity interest by or in such Entity. 

“Business Day” means any day excepting a statutory holiday in the Province of Ontario or a Saturday or
a Sunday. 
 “Calendar Quarter” means a period of three (3) months in the Gregorian
calendar ending on the last day of March, June, September, or December. 
 “Commercial Sale”
means the sale of a Licensed Product for consideration. 
 “Co-Owned Technologies” means
technology, including all corresponding intellectual property rights thereto, developed, conceived or conceived and reduced to practice jointly by both employees, contractors or agents of Licensor and employees, contractors and agents of Licensee.

 “Covered by the Licensed Patents” means that, in respect of a Licensed Product, the
manufacture, use, sale or import of such Licensed Product would infringe, but for the License granted hereunder, a Valid Claim in the Licensed Patents in the country in which such Licensed Product is manufactured, used, sold or imported. 

“Confidential Information” means any information disclosed under this Agreement and designated as being
confidential or proprietary including but not limited to information relating to any scientific or engineering research project, inventions, discoveries, methods, processes, work in process, future developments, names of suppliers and customers,
marketing and business plans relating to a party (the “Disclosing Party”), whether in oral, written, graphic or electronic form. Confidential Information shall not include information that is: (i) known to the other
party (the “Receiving Party”) prior to disclosure by the Disclosing Party, as evidenced by prior written business records; (ii) disclosed in published literature, other than by Receiving Party in violation of this
Agreement; (iii) generally known or available to 

  

			
		  	Page 2 of 26

 
industry prior to disclosure by the Disclosing Party; (iv) obtained by the Receiving Party from a third party who is not in breach of any confidentiality obligations to the Disclosing Party;
(v) independently developed by the Receiving Party without any reference to confidential or proprietary information received from the Disclosing Party; (vi) approved in writing by the Disclosing Party for disclosure; or (vii) is
required to be disclosed by operation of law or court order, provided the Receiving Party makes reasonable efforts to provide the Disclosing Party with notice of such requirement prior to any such disclosure by the Receiving Party and reasonably
assists the Disclosing Party, at the Disclosing Party’s expense, in avoiding and minimizing such disclosure or obtaining confidential treatment of such information required to be disclosed, to the extent possible. 

“Effective Date” means the date this Agreement is made effective, as first written above. 

“Entity” means a corporation, an association, a joint venture, a partnership, a trust, a business, an
individual, a government or political subdivision thereof, including an agency, or any other organization, which can exercise independent legal standing. 
 “Field of Use” means all fields. 

“Gross Revenues” means all cash, monies, receipts and other consideration received by the Licensee or
its Affiliates arising from or in connection with Commercial Sales including royalties received by Licensor or its Affiliates from Sublicensees. If consideration is received in a form other than cash, Gross Revenue shall be the monetary equivalent
or fair market value of such consideration, whichever is greater. 
 “Improvement” means any
development, modification, enhancement, or addition to the subject matter of the Licensed Patents, Licensed Product, and Licensed Technology, as applicable, developed by Principal Investigators pursuant to any Sponsored Research Agreement between
Licensee and Licensor, and “Improvements” shall be the plural of any Improvement. 

“Licensed Patents” means (i) the claims of the patent applications identified in Exhibit A,
(ii) any international patent applications corresponding to the foregoing, and (iii) any and all continuations, continuations-in-part, divisions, reissues,
reexaminations, or extensions of the foregoing, and all patents that issue from any of the foregoing applications; and (iv) any patent applications for Improvements to the subject matter of subparagraphs (i), (ii), and (iii). For the avoidance
of doubt, Licensed Patents shall include Licensor’s ownership in and to any of the foregoing with respect to Co-Owned Technologies. 
 “Licensed Product” means any product, apparatus, method, process or service in the Field of Use that is covered by the Licensed Patents or uses or incorporates any Licensed Technology.

 “Licensed Technology” means (i) the technologies contained in the Licensed Patents
added to Exhibit A hereto by mutual written agreement of the parties and (ii) any Improvements thereto. 

  

			
		  	Page 3 of 26

 “License” means the license rights granted in Article 2 of
this Agreement. 
 “Net Sales” means Gross Revenues actually received by Licensee or its
Affiliates from a third party arising from a Commercial Sale of any Licensed Product, but excluding any Licensed Product furnished to any third party at-cost for research, testing and/or regulatory purposes, reduced by the following costs actually
allowed and/or incurred by Licensee or its Affiliates in relation to the Commercial Sale of Licensed Products, as appropriate, and as evidenced by written business records: 

 

	 	(a)	discounts, charge backs, returns, recalls, allowances for bad debts or 

  

	 	    	uncollectible amounts and rebates; 

  

	 	(b)	credits or refunds, not exceeding the original or customary billing or invoice amount, for claims or returns; 

 

	 	(c)	transportation insurance premiums; 

  

	 	(d)	reasonable outbound freight and other transportation expenses; 

  

	 	(e)	discounts, in amounts customary in the trade, for quantity purchases, cash payments, prompt payments, wholesalers, and distributors; and 

 

	 	(f)	taxes including sales, use, turnover, value-added, excise, import, export, withholding and other taxes, duties, or tariffs imposed by a government agency on such
Commercial Sale and borne by Licensee or its Affiliates, except tax related to income derived by Licensee or its Affiliate’s from such Commercial Sale. 

“Principal Investigators” means Dr. Lynn Megeney and Dr. Michael Rudnicki. 

“Sublicensee” means any Entity that is expressly licensed by Licensee, pursuant to the authority
granted in this Agreement to grant sublicenses. 
 “Valid Claim” means a claim in an unexpired
issued Licensed Patent that has not been held invalid or unenforceable by the final, unappealable decision of a court, or similar legal entity, of competent jurisdiction. 

 

	1.2	Entire Agreement 

 This
Agreement, including the Exhibits appended hereto, constitute the entire agreement and understanding between Licensor and Licensee pertaining to the subject matter hereof and supersedes all prior agreements, understandings, negotiations and
discussions pertaining to such subject matter, whether oral or written or in electronic form, specifically including the First License Agreement in its entirety. Except as specifically set out herein, there are no conditions, representations,
warranties, undertakings, promises, inducements, or agreements whether direct, indirect, collateral, express or implied made by Licensor to Licensee. No modification, supplement or waiver of this Agreement shall be binding unless executed in writing
by authorized officers of each party. 

  

			
		  	Page 4 of 26

	1.3	Force Majeure 

 Neither
Licensor nor Licensee shall be in default of the terms of this Agreement because the party delays performance or fails to perform such terms; provided such delay or failure is not the result of the party’s intentional or negligent acts or
omissions, but the result of causes beyond the reasonable control of such party. Causes reasonably beyond the control of Licensor and Licensee shall include, but not be limited to, revolutions; civil disobedience; fires; acts of God, war, or public
enemies; blockades; embargoes; strikes; labour disputes; laws; governmental, administrative or judicial orders, proclamations, regulations, ordinances, demands, or requirements; delays in transit or deliveries; or inability to secure necessary
permits, permissions, raw materials, or equipment, except to the extent such event shall be within the control of the party seeking to rely on the provisions of this Article 1.3. 

 

	1.4	Governing Law 

 This
Agreement shall be governed and construed in accordance with the laws of the Province of Ontario, and the laws of Canada applicable therein, without regard to any choice or conflict of laws, rule or principle that would result in the application of
the laws of any other jurisdiction. Each of the parties irrevocably consents to the exclusive jurisdiction of the federal and provincial courts located in Ontario. 
  

	1.5	Headings 

 The article,
section and subsection titles and headings contained in this Agreement are for convenience and reference only. Such titles and headings do not form a part of this Agreement, shall not define or limit the scope of the articles, sections or
subsections, and shall not affect the construction or interpretation of any of the articles, sections or subsections. 
  

	1.6	Severability 

 If a court
or other lawful authority of competent jurisdiction declares any provision, Article or Section of this Agreement invalid, illegal or unenforceable, this Agreement will continue in full force and effect with respect to all other provisions, Articles
and Sections and all rights and remedies accrued under such other provisions, Articles and Sections will survive any such declaration. The parties shall, in good faith, negotiate substitute terms for any provision so declared illegal or
unenforceable, which shall most nearly approximate the intent of the parties at the time they entered into this Agreement. 

  

			
		  	Page 5 of 26

 Article 2 
 GRANT OF RIGHTS 
  

	2.1	License 

 Subject to the
terms and conditions of this Agreement, Licensor hereby grants to Licensee the exclusive (subject to 2.2), world-wide, royalty bearing right and license (with the right to sublicense) to use Licensor’s
rights in and to the Licensed Technology and the Licensed Patents in the Field of Use to develop Licensed Products and to make, have made, import, use, offer for sale and sell Licensed Products. 

 

	2.2	Rights Retained by Licensor 

  

	 	2.2.1	Licensed Technology and Licensed Patents 

 Notwithstanding the foregoing, Licensor retains the right to use and practice the Licensed Technology and the Licensed Patents within the Field of Use for
non-commercial, research and/or academic purposes only. 
  

	 	2.2.2	Access to and Publication of Licensee Data by Licensor 

 In the event that Licensee’s license to any of the Licensed Patents terminates, or upon Licensee’s bankruptcy, insolvency, or dissolution, Licensee will grant to the Licensor a fully paid-up,
royalty-free, perpetual, irrevocable, worldwide right and license to use any Licensee generated data related to such Licensed Patents to publish and/or publicly disclose the data, subject to the following provisions. Prior to any such publication or
public disclosure of any Licensee generated data, methods, or results related to the Licensed Patents, Licensor will provide copies of the planned disclosure for Licensee’s review. Licensee will have a period of thirty (30) days to review
the planned disclosure (the “Review Period”) and, if Licensee determines that the disclosure contains potentially patentable subject matter or other Confidential Information, then the Review Period will be extended for up to
ninety (90) days to allow for the protection of Licensee’s interests, including the preparation of patent applications and/or the removal of Confidential Information of Licensee; provided, however, that in the event that proceedings by or
against Licensee are instituted in bankruptcy under any insolvency law, Licensor may proceed with such publication or public disclosure unless Licensee requests a delay of publication, in writing, within ninety (90) days of Licensor providing
copies of the planned disclosure. In the event the Licensee is successful in raising additional financing and maintains ownership of the data it has generated, Licensee will review and discuss, reasonably and in good faith, with Licensor the
publication of any Licensee generated data if the Principal Investigators or any other Licensor personnel had any involvement in the research that generated the data. Nothing herein shall restrict Licensor from publishing data generated by Licensor,
its employees, contractors and agents relating to the Licensed Patents, provided no Confidential Information of Licensee is contained in any such publication without Licensee’s prior written permission, which shall not be unreasonably withheld
or delayed. If Licensor conducts research that is sponsored by Licensee under a separate sponsored research agreement, publication of data resulting from such sponsored research agreement shall be governed by the publication terms of said research
agreement, which terms will provide for reasonable review by Licensee of any proposed publication of research results sponsored by Licensee to identify patentable subject matter that should be protected by the filing of a patent application(s).

  

			
		  	Page 6 of 26

	2.3	No rights in Licensed Patents and Licensed Technology 

 Each party acknowledges that the rights and licenses granted under this Agreement are limited to the scope expressly granted. Accordingly, except for the rights expressly granted under this Agreement, no
right, title, or interest of any nature whatsoever is granted by either party to the other party. 
  

	2.4	Rights to Sublicense 

 The
License granted under this Agreement specifically includes the right of Licensee to grant sublicenses. Licensee agrees that any sublicense it grants to any third party shall be granted under the following conditions: 

 

	 	a.	Any sublicense grant of rights to the Licensed Technology and/or the Licensed Patents shall be restricted to the Field of Use and shall be subject to substantially the
same terms and conditions as set out in this Agreement (the “Sublicense Agreement”), with the exception of those terms and conditions that relate to additional royalties and additional consideration that Licensee may require
a Sublicensee to pay to Licensee under the Sublicense Agreement, provided that [***]. Each Sublicense Agreement shall specifically reference this Agreement and all rights retained by Licensor. 

 

	 	b.	Licensee shall provide to Licensor a fully executed copy of the Sublicense Agreement within fifteen (15) days following execution of the same.

 Article 3 
 TERM 
  

	3.1	Term 

 The term of this
Agreement, and the license granted under Section 2.1 hereof, shall commence on the Effective Date and, unless otherwise terminated earlier pursuant to the terms of this Agreement, shall extend until the last patent of Licensed Patents expires.

 Article 4 
 LICENSING CONSIDERATION, OPTION and COMMERCIALIZATION 
  

	4.1	Up-Front Payments 

 In
consideration for the license granted in this Agreement, Licensee shall pay to Licensor, the following payments: 
  

	 	a.	 The parties acknowledge that, pursuant to the First License Agreement, Licensee reimbursed Licensor for all past patent related costs incurred by
Licensor retroactively to May 31, 2008 and prior to December 22, 2008 pertaining to patent families 1, 2, 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission

  

			
		  	Page 7 of 26

	 	
and 3, and 50% of past patent costs relating to patent family 7 as set out in Exhibit “A” to the Agreement, as invoiced by Licensor to Licensee, which amounts are non-refundable.
Licensee shall not be required to reimburse Licensor for any past patent related costs incurred by Licensor prior to December 22, 2008 pertaining to patent family 4 of Exhibit “A”, for which Licensee and Licensor shall bear their own
costs, except as provided by Section 4.1(c) below; 

  

	 	b.	Upon the Effective Date of this Agreement, Licensee shall pay to Licensor the amount of thirty-seven thousand dollars Canadian ($37,000 Cdn), which amount shall be
non-refundable; and 

  

	 	c.	Upon Licensee notifying Licensor, which it must do in writing prior to March 31, 2011, of its intention to retain its license to patent family 4 of Exhibit
“A”, Licensee shall pay to the Licensor thirty-one thousand dollars Canadian ($31,000 Cdn), which amount shall be non-refundable. 

  

	4.2	Earned Royalties 

 In
consideration for the license granted in this Agreement and for the term of this Agreement, Licensee shall pay to Licensor, in the manner designated in this Agreement, an earned royalty as follows: [***]% of Net Sales. 

Notwithstanding the foregoing, in the event such earned royalty relates to a Licensed Patent arising from Co-Owned Technologies, such
earned royalty shall be reduced in a manner to reflect Licensor’s relative contribution and ownership of such Licensed Patent, as specified in Exhibit B. 
  

	4.3	Annual License Fee 

 As a
condition to maintain this Agreement and commencing on the first anniversary date of execution of this Agreement, Licensee shall pay to Licensor an annual license fee of [***] dollars Canadian ($[***] Cdn) for each calendar year this Agreement is in
effect. Any maintenance payment due shall be paid with Licensee’s final earned royalty report and payment for the appropriate calendar year. All maintenance payments will be fully creditable towards earned royalties, milestone payments and
sublicensing revenue payments only for the specific year in which the maintenance payment is due. 
  

	4.4	Milestone Payments 

  

					
	 Amount
 Cdn $
	 	  	Milestone Event
	$	[***]	  	  	[***]
		
	$	[***]	  	  	[***]
		
	$	[***]	  	  	[***]
		
	$	[***]	  	  	[***]

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission

  

			
		  	Page 8 of 26

 Notwithstanding the foregoing, in the event such milestone payment relates to a Licensed
Product covered by a Licensed Patent arising from Co-Owned Technologies, such milestone payment shall be reduced in a manner to reflect Licensor’s relative contribution and ownership of such Licensed Patent, as specified in Exhibit B.

  

	4.5	Sublicensing Revenue 

 In
addition to all other royalties and fees payable hereunder, Licensee will pay to Licensor a portion of all other consideration, whether cash or cash in-kind, received by Licensee, where such consideration is
exchanged for rights granted to a Sublicensee pursuant to this Agreement, as follows: [***] percent ([***]%) of all consideration received where the sublicense is executed between [***]; [***] percent ([***]%) of all consideration received where the
sublicense is executed between [***]; and, [***] percent ([***]%) thereafter. 
 Notwithstanding the foregoing, in the event such
consideration includes Co-Owned Technologies, such consideration shall be reduced in a manner to reflect Licensor’s relative contribution and ownership of such Co-Owned Technologies, as specified in Exhibit B. 

 

	4.6	Royalty Stacking 

 The
parties recognize and agree that, in order for Licensee and/or its Sublicensees to develop and commercialize the Licensed Technology and/or Licensed Product within the Field of Use and Territory, it may be necessary for Licensee and/or its
Sublicensees to make use of and/or incorporate multiple elements of third party intellectual property from multiple sources. Licensee will determine, acting reasonably and in good faith, which elements of third party intellectual property are
required for the development and commercialization of the Licensed Technology and/or Licensed Product. Royalty payments or license fees may be required to be paid by Licensee and/or its Sublicensees to third parties if intellectual property owned by
a third party is required for the commercialization of the Licensed Technology and/or Licensed Products in the Field of Use and Territory. All commercially reasonable payments to third parties that Licensee and/or its Sublicensees are required to
pay to obtain licenses or other rights to use or incorporate third party intellectual property or products that are required for the development and commercialization of a Licensed Technology and/or Licensed Product in the Field Of Use and Territory
will be creditable in the year they are paid by Licensee and/or its Sublicensees against royalties otherwise owed to Licensor hereunder in that same year for that same Licensed Technology or Licensed Product, provided that [***];
provided, that in no one year will such expenses be credited against more than [***]% of royalty payments otherwise owed to Licensor. In any event, in order for payments to third parties to be credited, such payments must have been commercially
reasonable and have to have been made in good faith. 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission

  

			
		  	Page 9 of 26

	4.7	Research Funding 

 The
parties agree to confer with each other from time to time, but no less than once every [***], to consider additional research project(s) of Principal Investigator(s) which Licensee may wish to sponsor. Licensee will review and evaluate such
project(s) in good faith, and the parties may negotiate a sponsored research agreement with respect to such project(s) upon the mutual consent of both parties. 
  

	4.8	Equity 

 The parties
acknowledge that, upon execution of the First License Agreement, Licensor, [***] were issued a combined total of [***]% of the original equity in Licensee, which equity was divided between Licensor and these investigators as follows: [***]

 Article 5 
 PAYMENTS AND REPORTS 
 Article 

 

	5.1	Payments 

 Unless
otherwise specified in this Agreement, including Article 4.3 above, all amounts due Licensor shall be paid quarterly within thirty (30) days following the end of each Calendar Quarter based on Net Sales for each such Calendar Quarter. All such
payments shall be remitted to Licensor’s address given in the notification provision of this Agreement or to such other address as Licensor shall direct. 
  

	5.2	Payments in Canadian Dollars 

 All amounts due Licensor under this Agreement are in Canadian dollars and are to be paid in Canadian dollars. With respect to Net Sales received by Licensee and its Affiliates in currency other than
Canadian dollars, calculations required to ascertain amounts due Licensor and any currency conversion necessary to make payment of amounts due Licensor shall be made using the official exchange rate quoted by the Royal Bank of Canada on the day
transfer of funds is actually made. If such currency conversion is not reasonably possible, Licensee shall deposit any amounts owed to Licensor, in the currency of the Net Sales received, in the bank or trust association of the country of such
currency designated by Licensor. 
  

	5.3	Late Fees 

 If any payment
is made more than thirty (30) days late after the date such payment is due (an “Overdue Payment”), Licensee shall pay to Licensor interest on an Overdue Payment at a rate of [***]. Such interest will accrue on an Overdue
Payment from the thirtieth (30th) day after the payment was due. Accrued interest will be due and payable on the first day of each month after interest begins to accrue, until full payment of such Overdue Payments and accrued interest is
received by Licensor. 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission

  

			
		  	Page 10 of 26

	5.4	Reports 

 During the term
of this Agreement and for two years thereafter, Licensee shall keep, at its own expense, accurate books of account using accepted accounting procedures, detailing all data necessary to calculate any payments due Licensor from Licensee under this
Agreement. Each payment made to Licensor shall be accompanied by a written report summarizing the data used to calculate the amounts paid. Each report pertaining to royalty payments for the applicable accounting period shall specifically include the
following, as applicable, as well as any other information reasonably requested by Licensor with notice to Licensee: 
  

	 	i.	itemized description of Licensed Products sold by Licensee, its Affiliates and its Sublicensees including, without limitation, quantity; 

 

	 	ii.	Net Sales amounts and details of calculations used to calculate Net Sales; 

 

	 	iii.	Royalties due, broken down by category and country; and 

  

	 	iv.	Sublicensing consideration received by Licensee or its Affiliates. 

 All reports under this Section 5.4 will be treated as Confidential Information of the Licensee. 
 If during any quarterly reporting period, no Net Sales are invoiced, billed, or received and no payment is due to Licensor, Licensee shall nevertheless timely submit a written report to Licensor stating
that no Net Sales were invoiced, billed, or received and no funds are due Licensor. 
  

	5.5	Examination of Records 

Upon at least fifteen (15) days’ written notice, Licensor shall have the right, through an independent, certified accounting
firm, to examine such records and books of account of Licensee and its Affiliates as are necessary to verify the accuracy of Licensee’s royalty payments hereunder. Such right may be exercised only once during any
twelve-month period. Such examination may be performed at any time within two (2) years after the end of the reporting period to which the books of account pertain, and shall be performed during normal
business hours at Licensee’s or an Affiliate’s major place of business or at such other site as may be agreed upon by Licensor and Licensee. The accounting firm may make abstracts or copies of such books of account solely for its use in
performing the examination. Licensor shall require, prior to any such examination, such accounting firm to agree in writing that such firm will maintain all information, abstracts, and copies acquired during such examination in strict confidence and
will not make any use of such material other than to confirm to Licensor the accuracy of Licensee payments hereunder. 
  

	5.6	Results of Examination 

If any examination of the Licensee’s records shows that Licensee has paid more than required under this Agreement, any excess amounts
shall, at Licensee’s option, be promptly 

  

			
		  	Page 11 of 26

 
refunded or credited against future royalties with interest from the date of overpayment at [***]. If any examination of the Licensee’s records shows that Licensee has paid less than
required under this Agreement, Licensee shall promptly pay the additional amount due together with interest and late fees as required under this Agreement for late payments. If the amount of underpayment exceeds [***] percent ([***]%) of the amount
which should have been paid, Licensee shall also pay all reasonable costs of such examination. 
 Article 6 

PERFORMANCE 
  

	6.1	Licensee Efforts 

 During
the term of this Agreement, Licensee shall use commercially reasonable efforts to exploit the Licensed Patents and/or Licensed Technology in the Field of Use in countries where it is commercially reasonable to develop Licensed Products hereunder,
and to achieve the following development benchmarks (“Benchmarks”) within the following time periods as set forth below: 
  

			
	Benchmark	  	Timeline
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 In addition, Licensee will use commercially reasonable efforts to commercialize and market all Licensed
Products as soon as practicable in accordance with the terms of a development plan prepared by Licensee within ninety (90) days of the Effective Date of this Agreement. Licensee will provide Licensor with (i) annual updates of the
development plan, (ii) clear and comprehensive documentation of its investment in the development of Licensed Products, and (iii) annual written progress reports outlining the development, evaluation, testing and commercialization of all
Licensed Products. 
 Licensee and Licensor agree to jointly and thoroughly review and discuss
Licensee’s efforts within six (6) months of the third (3rd) anniversary of this Agreement. Acting reasonably and in good faith, Licensee and Licensor will determine if any Licensed Product is not being actively developed, evaluated, tested or commercialized
and Licensee agrees to review its interest in maintaining its license to the Licensed Patent of any such Licensed Product. 
 For
each Licensed Patent, in the event (i) Licensee is unable to achieve a given Benchmark for a Licensed Product covered by such Licensed Patent in accordance with its applicable timeline and (ii) Licensor determines, acting reasonably, that
commercially reasonable 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission

  

			
		  	Page 12 of 26

 
efforts are not being made by the Licensee to develop a Licensed Product covered by such Licensed Patent, Licensor may deliver written notice to Licensee of such non-performance. In the event
Licensee has not cured the deficiencies outlined in such written notice within sixty (60) days after such written notice was received by Licensee, Licensor may, solely with respect to such Licensed Patent that is the subject of such
non-performance, render the license to such Licensed Patent non-exclusive or terminate the license to such Licensed Patent, at the sole discretion of Licensor, upon written notice to Licensee of Licensor’s decision. 

Notwithstanding anything to the contrary in the Agreement, in the event that Licensee is unable to achieve a given Benchmark according to
its applicable timeline, Licensee may, [***] for each Licensed Patent under the Agreement, extend the timeline by [***] by making a [***] dollars Canadian ($[***] Cdn) payment to Licensor (where, for the avoidance of doubt, all later occurring
Benchmark(s) shall also be similarly extended by [***]). 
 If Licensee fails to reimburse Licensor for any patent costs for any
Licensed Patents, the license rights to such Licensed Patents and the Licensed Technology they cover cease to be part of the license granted to Licensee under this Agreement and all license rights to such Licensed Patents and the Licensed Technology
they cover will automatically return to Licensor to deal with at its sole discretion without any obligation to Licensee; provided, however, that Licensor has given Licensee written notice of any overdue payment owed by Licensee and Licensor fails to
make such payment within thirty (30) days of receipt of such overdue payment notice. For clarity, Licensee will still be liable to Licensor for any outstanding patent costs incurred up to and including the date that the license to any such
Licensed Technology and Licensed Patents is terminated. 
 Article 7 

INTELLECTUAL PROPERTY MATTERS 
  

	7.1	Licensed Patents 

Licensee shall be responsible for all further patent prosecution with respect to the Licensed Patents and Licensed Technologies set out in
Exhibit “A”. Licensee may select the patent agent for the prosecution of the Licensed Patents, subject to the approval of Licensor as the patent owner, which approval will not be unreasonably withheld. Licensee shall provide Licensor with
copies of all relevant documentation related to the filing and prosecution of the Licensed Patents so that Licensor may be informed and apprised of and meaningfully consulted as to the continuing prosecution. Licensor shall keep all such
documentation confidential. In the event the Licensee does not agree that any given patent application or patent should be filed, prosecuted or maintained (hereinafter referred to as a “Refused Licensed Patent”) in a
particular jurisdiction(s) Licensee shall indicate such disagreement in writing (hereinafter “Refusal Notice”) and upon Licensor’s receipt of such Refusal Notice Licensor shall have the right unilaterally to make,
prosecute and maintain such Refused Licensed 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission

  

			
		  	Page 13 of 26

 
Patent in such jurisdiction(s) in the name of its owners, at Licensor’s expense, and Licensee shall not have any rights or obligations to such Refused Licensed Patent in such
jurisdiction(s); provided, however, that Licensee shall retain all of its ownership rights in any Refused Licensed Patent that is a Co-Owned Technology. In such case Licensor shall provide Licensee with copies of all relevant documentation related
to the filing and prosecution of the Refused Licensed Patents so that Licensee may be informed and apprised of and be meaningfully consulted with as to the continuing prosecution. Licensor shall have no obligation to continue prosecution or
maintenance of any Refused Licensed Patent and may abandon same without any prior notice or any obligation to Licensee. 
 Both
Licensee and Licensor shall make best efforts to respond promptly to any request from the other Party for input or assistance with respect to matters pertaining to the Licensed Patents. Licensee shall use reasonable efforts to amend any patent
application to include claims reasonably requested by the other Party and required to protect the Licensed Technology. 
 In
addition to Licensee’s obligations pursuant to section 4.1 above, Licensee shall be solely responsible for all patent and legal costs relating to the Licensed Patents and Licensed Technology (excluding Refused Licensed Patents) from the
Effective Date onward, including all costs relating to the transfer of the Licensed Patents to the new patent agents selected by Licensee and approved by Licensor. For any patent and legal costs relating to the Licensed Patents and Licensed
Technology (excluding Refused Licensed Patents) paid by Licensor after the Effective Date (including, without limitation, those expenses related to patentability assessments and drafting, filing, prosecution, maintenance, and taxes (the
“Patent Costs”)), Licensee shall promptly reimburse Licensor for such Patent Costs upon receipt of an invoice from Licensor for such expenses. For any work in progress with respect to the Licensed Patents for which the Patent
Costs have not already been paid by Licensor to its patent firm prior to the transfer of the Licensed Patents to Licensee’s patent agent, Licensor will direct its patent firm to copy Licensee on all such invoices from said patent firm and
Licensee will promptly pay said invoices directly to Licensor’s patent firm. 
  

	7.2	Patent Markings 

 Licensee
shall comply with all applicable Canadian, United States and other foreign statutes relating to the marking of Licensed Product(s) and/or related packaging with patent pending, patent number(s), copyrights, or other intellectual property notices and
legends required to maintain the intellectual property rights licensed under this Agreement. 
  

	7.3	Ownership of Technology 

Subject only to the licenses granted to Licensee hereunder, all rights, title, and interest with respect to Licensed Patents and Licensed
Technology that are not specifically granted herein are reserved to the owner thereof. 

  

			
		  	Page 14 of 26

 Article 8 
 WARRANTIES 
  

	8.1	Licensor Warranties 

Licensor represents and warrants that: 
  

	 	a.	[***]; 

  

	 	b.	Licensor has not granted to any other Entity any rights or licenses under the Licensed Technology or the Licensed Patents; and 

 

	 	c.	As of the Effective Date, Licensor is not aware of, nor has Licensor received notice of any allegations or claims that the Licensed Technology or Licensed Patents
infringe the patent rights of any third party. Licensee acknowledges and accepts that Licensor has made no inquiries or undertaken any due diligence with respect to this warranty and said warranty is limited to the immediate knowledge of the
Licensor, without further inquiry. 

  

	8.2	Limitation on Licensor’s Warranties 

 LICENSOR MAKES NO WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE LICENSED PATENTS OR THE LICENSED TECHNOLOGY, OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT. ALL LICENSED PATENTS
AND LICENSED TECHNOLOGY ARE MADE AVAILABLE TO LICENSEE STRICTLY ON AN “AS IS” BASIS. LICENSOR DOES NOT WARRANT THAT THE LICENSED PATENTS OR THE LICENSED TECHNOLOGY IS ERROR FREE OR THAT IT WILL MEET LICENSEE’S REQUIREMENTS. ALL
IMPLIED WARRANTIES AND CONDITIONS OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE EXPRESSLY DISCLAIMED AND EXCLUDED. THE ENTIRE RISK AS TO THE RESULTS AND PERFORMANCE AND USE OF LICENSED TECHNOLOGY, LICENSED PATENTS, AND ANY PRODUCTS,
SERVICES OR METHODS BASED ON THE LICENSED TECHNOLOGY IS ASSUIMED BY LICENSEE. OTHER THAN THOSE WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT, LICENSOR SPECIFICALLY DOES NOT MAKE ANY WARRANTIES OR REPRESENTATIONS, EXPRESS OR IMPLIED, CONCERNING
THE PATENTABILITY OF ANY LICENSED TECHNOLOGY, THE VALIDITY OF ANY LICENSED PATENT(S), THE SCOPE OF ANY LICENSED PATENT(S) CLAIMS, OR WHETHER OR NOT THE EXERCISE OF THE RIGHTS LICENSED UNDER THIS AGREEMENT WILL OR WILL NOT RESULT IN INFRINGEMENT OF
ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
  

	8.3	Licensee’s Indemnification 

 Licensee hereby indemnifies and undertakes to defend Licensor, the Ottawa Hospital and all their respective affiliates, officers, directors, employees, students, representatives, agents, consultants and
contractors (“Indemnified Parties”) and hold them harmless against all claims, suits, proceedings, demands, actions of any nature or kind whatsoever asserted against Indemnified Parties (“Claims”), and
liabilities, damages, judgments, costs, 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission

  

			
		  	Page 15 of 26

 
expenses and fees incurred by Indemnified Parties as a result of Claims (including but without limitation, reasonable legal expenses) (“Losses”), to the extent that such
Claims arise out of or are in any way associated with this Agreement including, without limitation, the development, use, manufacture, marketing, promotion, sale or other disposition of the Licensed Products or the use of Licensed Patents or
Licensed Technology by Licensee, its Affiliates or Sub-licensees or other third parties; any loss, cost or expense incurred by the Indemnified Parties relating to claims that the Licensed Products or Licensed Technology infringe the patent rights or
other proprietary rights of a third party; and, solely with respect to Claims by third parties, any material breach by Company or its Affiliates or Sublicensees of the Agreement, except in each case to the extent such Claims or Losses result from
the gross negligence or willful malfeasance of the Indemnified Parties. 
 Licensee agrees to pay promptly to Licensor the amount
of all Losses to which the foregoing indemnity relates. The indemnification rights of the Licensor herein are in addition to all rights which Licensor may have at law or in equity or otherwise. 

This indemnification clause shall survive the termination or expiration of this Agreement. 

 

	8.4	Insurance 

 Prior to the
first clinical trials involving humans or the first Commercial Sale of Licensed Product, whichever occurs earliest, Company shall promptly obtain and maintain comprehensive general liability insurance which shall insure against no less than the
following risks: bodily injury, personal injury, liability, property damage, products liability, and other types of insurance in type and amount considered reasonable and prudent in the industry given the types of risks involved in the development,
pre-commercialization (including, without limitation, clinical trials) and commercialization of the Licensed Products and Licensed Technology, but in no event less than [***] dollars ($[***]) per occurrence and [***] dollars ($[***]) in the annual
aggregate. Company shall maintain such coverage with a third party commercial insurance carrier(s) rated A or better. Company shall cause the insurance carrier to include the Licensor, and the Ottawa Hospital as named additional insureds on all such
policies. Company shall provide Licensor with copies of the endorsements to such policies naming Licensor, and the Ottawa Hospital as additional insureds. Company shall instruct its insurance carrier(s) providing such coverage to notify Licensor in
writing thirty (30) days prior to any material change in coverage provided by such policies. The reference above to a minimum insurance requirement in no way limits the liability of Licensee hereunder to that amount, and for clarity the
Licensee shall be responsible for properly insuring above the referenced minimum amount if it is reasonable and prudent in the industry to do so given the types of risks involved in the development, pre-commercialization (including, without
limitation, clinical trials) and commercialization of the Licensed Products and Licensed Technology. This insurance clause shall survive termination or expiration of this Agreement. 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission

  

			
		  	Page 16 of 26

	8.5	Consequential Damages 

Except for any damages arising pursuant to a breach of Article 10, neither party shall have any liability of any kind to the other party
for any indirect, incidental, special or consequential damages, however caused, even if such other party has been advised of the possibility of such damages. 
 Article 9 
 INFRINGEMENT 

 

	9.1	Licensed Technology Infringes Third Party’s Rights 

 Should any third party threaten or make a claim that the manufacture, use, import or sale of a Licensed Product or the use of the Licensed Patents or the Licensed Technology by Licensee infringes or
constitutes wrongful use of such third party’s intellectual property rights, Licensee shall give Licensor prompt written notice detailing as many facts as possible concerning such claim. Licensor agrees, at Licensee’s expense, to provide
all necessary assistance to Licensee in its attempts to resolve such claims. To the extent that such claims are based solely on the use or practice of the subject matter Covered by the Licensed Patents or the Licensed Technology, Licensee may credit
any reasonable legal costs, expenses, and fees expended by Licensee in defending against any such claims against earned royalties from sales of Licensed Products in those countries where such Licensed Products or the Licensed Technology are subject
to such claims, up to a maximum credit of [***] percent ([***]%) of the earned royalties owing to Licensor hereunder. Licensee shall not enter into any agreement to settle any such claim without the prior written approval of the Licensor, which
shall not be unreasonably withheld or delayed. Any award or settlement amount received by Licensee shall first be applied to Licensee’s reasonable un-recovered legal costs of the action and then to payment to Licensor of any royalties that were
credited as outlined above. 
  

	9.2	Third Party Infringement 

Licensor and Licensee agree that, should either party become aware of, any actual or potential infringement or wrongful use of the
Licensed Technology and/or the Licensed Patents, that party will give the other party prompt notice detailing as many facts as possible concerning such infringement or potential infringement or wrongful use. During the term of this Agreement,
Licensee, at its own expense, shall have the right to prosecute infringement or wrongful use of the Licensed Technology and/or the Licensed Patents in the Field of Use. Licensee shall have the right to join Licensor as a party plaintiff in any
action brought by Licensee to enforce the Licensed Technology and/or Licensed Patents. Should Licensee join Licensor, Licensee shall pay all expenses incurred by Licensor in its participation in the action, and Licensee shall indemnify the
Indemnified Parties against any losses, judgments, or awards that the Indemnified Parties may incur as a result of such action. Licensee shall recover and retain any and all damages recovered from such an action after Licensor’s expenses are
paid, the Indemnified Parties are indemnified, all royalties and all other payments owing to Licensor under this Agreement have been paid in accordance with the Agreement, and Licensee’s reasonable legal expenses are paid, in that order. The
foregoing rights shall be subject to the continuing right of Licensor to intervene in an action commenced by Licensee at Licensor’s own expense. 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission

  

			
		  	Page 17 of 26

	9.3	Licensor Enforcement 

Should Licensee not commence an action against a third party that is infringing or wrongfully using the Licensed Technology and/or
Licensed Patents within one hundred and eighty (180) days of receiving notice of such infringement, then Licensor may, at its sole discretion, commence an action in its own name against such third party, at Licensor’s expense. Licensor
shall have the right to join Licensee as a party plaintiff in any action brought by Licensor to enforce the Licensed Technology and/or Licensed Patents intellectual property rights. Should Licensor join Licensee, Licensor shall pay all expenses
incurred by Licensee in its participation in the action. Licensor shall recover and retain any and all damages recovered from such an action 
 Article 10 
 CONFIDENTIAL INFORMATION 

 

	10.1	Confidential Information 

Licensor and Licensee may disclose to one another Confidential Information for the purposes contemplated in this Agreement. Licensor and
Licensee agree to use reasonable efforts to protect such Confidential Information and preserve its confidential and proprietary. Licensor and Licensee shall each use at least the same degree of care and precaution as is customarily used to protect
their own Confidential Information and which in any event shall be no less than the degree of care generally exercised in the industry to protect Confidential Information. Licensor and Licensee each agree that such party shall utilize all such
Confidential Information of the other solely for furthering the objectives of this Agreement and will not, either during the term of this Agreement or at any time subsequent to the termination of this Agreement, otherwise use such information of the
other for its own benefit or for the benefit of others; nor will such party publish or otherwise disclose such Confidential Information of the other to any other individual or entity without the prior written consent of the other. 

Article 11 

TERMINATION 
  

	11.1	Licensor’s Right to Terminate 

 Licensor may, at its option, terminate this Agreement immediately and without notice if Licensee: 
  

	 	a.	makes a general assignment for the benefit of creditors, suffers or permits the appointment of a receiver for its business or assets, or avails itself of, or becomes
subject to, any proceeding under any Bankruptcy and Insolvency Act or any other statute of any state or country relating to insolvency or the protection of creditor’s rights; or 

  

			
		  	Page 18 of 26

	 	b.	is in breach or default of any material obligation under this Agreement and fails to cure such breach or default, or satisfy that such breach or default has been cured,
or otherwise reach agreement with Licensor on a procedure to remedy the breach or default within sixty (60) days after receiving notice from Licensor to cure, except for failure of Licensee to reimburse Licensor for patent costs which breach or
default must be cured by Licensee within fifteen (15) days of receipt of notice from Licensor per Section 6.1 above. In the event that the claimed breach or default involves a dispute over royalties or other payments claimed to be owed by
Licensee hereunder, Licensee may satisfy its obligation to cure or remedy such claimed breach under this Section 11.1 by placing the amounts Licensor reasonably believes are owed to it in an escrow account, held by an unrelated third party
escrow agent, until such time as the dispute over such royalties or payments is resolved. 

  

	11.2	Licensee’s Right to Terminate: 

 Licensee may terminate this Agreement together with all licenses granted hereunder upon ninety (90) days prior written notice to Licensor. 

 

	11.3	Obligations on Termination 

Termination of this Agreement shall not release Licensor or Licensee from any obligation or liability to the other which shall have
matured or accrued prior to termination. The following rights and obligations, in addition to others as expressly provided herein, shall survive termination: 
  

	 	a.	Licensee shall make all reports as required herein prior to termination and shall submit a final report as reasonably requested by Licensor within sixty (60) days
of such request; 

  

	 	b.	Licensee shall pay all royalties or other payments due Licensor accrued or accruable for payment prior to termination, within thirty (30) days of the effective
date of termination; 

  

	 	c.	Licensee shall maintain all records required to be kept herein for the period before termination, and shall allow Licensor examination privileges as set forth in
Section 5.5 for twelve (12) months after the effective date of the termination; 

  

	 	d.	any licenses, releases, or agreements of non-assertion running in favour of end users of Licensed Products that have been
entered into by Licensee with the approval of Licensor; 

  

	 	e.	all claims and causes of action one party may have against the other; and 

  

	 	f.	all obligations to preserve and maintain the confidentiality of Confidential Information, except as required by court orders or by law or to satisfy government
regulations. 

  

			
		  	Page 19 of 26

	11.4	Assignment of Sublicenses 

Upon termination of this Agreement, Licensee agrees to assign to Licensor all its rights under the Sublicense Agreements granted under
this Agreement. All Sublicense Agreements shall contain the provision that Licensee may assign the Sublicense Agreements to Licensor if this Agreement is terminated; provided that Licensor shall not be required to accept such an assignment and may
terminate any such Sublicense Agreement without obligation or liability to Licensee or its Sublicensee if (i) Licensee has not complied with the requirements of Article 2.4 (Rights to Sublicense) of this Agreement; (ii) if such Sublicense
Agreement does not comply with Article 2.4 of this Agreement, or (iii) if Sublicensee is in breach of their Sublicense Agreement. 
 Article 12 
 GENERAL PROVISIONS 

 

	12.1	Alternative Dispute Resolution 

 In the event of any dispute or disagreement between the Licensor and Licensee with respect to the interpretation of any provision of this Agreement or the performance of Licensor or Licensee under this
Agreement, upon the written request of either party, Licensee, as represented by a designated representative of Licensee’s choice, and Licensor, as represented by a designated representative of Licensor’s choice, will meet for the purpose
of resolving such dispute or negotiating an adjustment or modification to such provision of this Agreement. The designated representatives will discuss the dispute and negotiate in good faith without the necessity of any formal proceedings related
thereto. The dispute shall be referred for non-binding alternative dispute resolution (“ADR”) by either party if the designated representatives have not been able to resolve the dispute within [***] of their first meeting. No
binding arbitration proceeding may be commenced unless the dispute is not settled within [***] of referral to ADR of such dispute. Licensee and Licensor shall share equally the costs of ADR. 

 

	12.2	Arbitration 

 Any dispute,
controversy, or claim between Licensor and Licensee, arising out of or relating to this Agreement or the breach, termination, interpretation, or invalidity thereof, which is not settled within [***] of referral to ADR of such dispute, shall be
settled, when permitted by law, final, by binding non-appealable arbitration under the following terms and conditions. 
  

	 	a.	Within [***] of the receipt of a demand for arbitration from the other party, Licensor and Licensee shall each select an arbitrator and give notice to the other party
of the selection, including the arbitrator’s name, address, and phone number. The two chosen arbitrators shall select a third arbitrator to act with them in the arbitration, 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission

  

			
		  	Page 20 of 26

	 	b.	The decision of a majority of the arbitrators will be final and binding upon Licensor and Licensee. Both Licensor and Licensee agree to accept and abide by the
decision. 

  

	 	c.	The arbitrator(s), in their discretion, shall allocate all costs of the arbitration between Licensor and Licensee. However, neither Licensor nor Licensee shall be
required to pay the costs of the other party and the arbitrator chosen by such other party. 

  

	 	d.	All arbitration authorized by this Agreement shall be conducted in accordance with the Arbitrations Act (Ontario). The award of the arbitrator shall be final and
binding upon the parties and all persons claiming through or under them. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction and thereupon execution or other legal process may issue thereon. The parties
hereto and all persons claiming through or under them hereby attorn to the jurisdiction of the arbitrator and to the jurisdiction of any court in which the judgment may be entered. 

 

	12.3	Arbitration-Administrative Considerations 

During any period of arbitration concerning this Agreement, this Agreement shall remain in full force and effect and all terms shall be
complied with by both Licensor and Licensee. 
  

	12.4	Assignment 

 This
Agreement may not be assigned or transferred by Licensee without the prior written consent of Licensor, which shall not be unreasonably withheld, except that, upon giving thirty (30) days advance written notice to Licensor, Licensee may assign
this Agreement without consent to (i) an Affiliate of Licensee provided such Affiliate first agrees in writing to abide by the terms of this Agreement, a copy of which agreement shall be promptly provided to Licensor, or (ii) a successor
to all or substantially all of the business of Licensee to which this Agreement relates, whether by merger, sale of stock, sale of assets or similar transaction, operation of law or otherwise. This Agreement shall enure to the benefit of and be
binding upon the parties hereto and their respective successors and permitted assigns. 

  

			
		  	Page 21 of 26

	12.5	Notices 

 Any demand,
notice or other communication to be given in connection with this Agreement shall be given in writing and shall be given by personal delivery, mail, courier, or by fax addressed to the recipient as follows: 

Licensor’s notification address: 
  

			
	The Ottawa Hospital Research Institute
	 General Campus, 5th Floor Critical Care Wing, room 5206b 501 Smyth Road
	  	
	 Ottawa, Ontario K1H 8L6, Canada

ATTN: Robert Hanlon, Chief Operating Officer
 Tel
no. (613) 739-6815            Fax no. (613) 739-6294
 Email:
rhanlon@ohri.ca
	  	

 Licensee’s notification address: 

	
	Verio Therapeutics Inc.
	[***]

 or to such other address, individual or electronic communication number as may be designated by notice
given by either party to the other. Any demand, notice or other communication given by personal delivery shall be conclusively deemed to have been given on the day of actual delivery thereof and, if given by electronic communication, on the day of
transmittal thereof if given during the normal business hours of the recipient and on the Business Day during regular business hours of the recipient and on the Business Day during which such business hours next occur if not given during such hours
on any day. 
  

	12.6	Waiver of Rights 

 In
order to be effective, any waiver, by either party, of any right under this Agreement, must be in writing signed by an authorized representative of the party making the waiver. No such waiver or failure of Licensor or Licensee to enforce a right or
strict performance under this Agreement shall be deemed to be a waiver or forbearance which would in any way prevent Licensor or Licensee from subsequently asserting or exercising any such rights, making a claim not specifically waived, or requiring
strict performance of this Agreement. No such waiver or failure to enforce shall affect the validity of this Agreement or be a continuing waiver excusing compliance with any provision of this Agreement in the future. 

 

	12.7	Publicity 

 Neither party
will use the name of the other party in any publicity without the prior written approval of the party being so named. Such approval from either party shall not be unreasonably withheld or delayed. Licensee, its Affiliates, Sub-Licensees, employees,
and agents will not use Licensor’s name, seal, logo, trademark, or service mark, or any adaptation of them, or the name, mark, or logo of any representative, organization or employee of Licensor in any way without the prior written consent of
Licensor in its sole discretion. 
  

	12.8	Interpretation 

 The
parties acknowledge that this Agreement has been the subject of full opportunity for negotiation and amendment and that the party who has taken the role of drafter shall not suffer any adverse construction of any terms or language of this Agreement
because of such role. 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission

  

			
		  	Page 22 of 26

	12.9	Time of the Essence 

 Time
is of the essence with respect to this Agreement. 
  

	12.10	Language 

 This Agreement
is drawn up only in English at the request of both parties. Les parties aux présentes conviennent que ce document soit rédigé en anglais seulement. 

  

			
		  	Page 23 of 26

 IN WITNESS WHEREOF, Licensor and Licensee have caused this Agreement to be executed
by their duly authorized representative. 
 IN WITNESS WHEREOF the parties have executed this Agreement on this 6th day of
April, 2010. 
  

									
	OTTAWA HOSPITAL RESEARCH INSTITUTE	 		 	Verio Therapeutics Inc.
					
	By:	 	/s/ Robert Hanlon	 		 	By	 	/s/ Frank Gleeson
					
	Typed Name:	 	ROBERT HANLON	 		 	Typed Name:	 	Frank Gleeson
					
	Title	 	Chief Operating Officer	 		 	Title:	 	
					
	Date	 	April 6/2010	 		 	Date:	 	April 6, 2010

  

			
		  	Page 24 of 26

 Exhibit A 
 Licensed Technology/Licensed Patents 
 [***] 

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission

  

			
		  	Page 25 of 26

 Exhibit B 
 Co-Owned Contribution 
 [***] 

 

					
	 Assignees /Co-Owners
	  	 OHRI
	  	 Verio Therapeutics

	Inventors	  	[***]	  	[***]
	Contribution	  	[***]	  	[***]

  
  

	*	Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission

  

			
		  	Page 26 of 26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]